

## CURRICULUM VITAE

August 1, 2018

David Winston Kimberlin, M.D.  
Department of Pediatrics  
Division of Pediatric Infectious Diseases  
University of Alabama at Birmingham  
1600 7th Avenue South, CHB 303  
Birmingham, Alabama 35233  
Phone: (205)996-6097  
FAX: (205)975-9972  
e-mail: dkimberlin@peds.uab.edu

**DATE OF BIRTH** May 9, 1963

**PLACE OF BIRTH** Austin, Texas

**MARITAL STATUS** Married  
Wife: Kim  
Children: Will, Claire, and Katherine

### EDUCATION

1985-1989 University of Texas Southwestern Medical School  
M.D.

1981-1985 Vanderbilt University, Nashville, Tennessee  
B.S. in Molecular Biology  
*summa cum laude*

1977-1981 Stephen F. Austin High School, Austin, Texas

### POST GRADUATE TRAINING

2013 Association of American Medical Colleges (AAMC)  
Executive Development Seminar for Interim and Aspiring  
Leaders

2013-2014 Fellow, Association of Medical School Pediatric  
Department Chairs' (AMSPDC) Leadership Development  
Fellowship Program

2009 Participant, inaugural class of the UAB Healthcare  
Leadership Academy

- 1999-2001 Participant, University of Alabama at Birmingham Clinical Research Training Program, Birmingham, Alabama. Supported by NIH K30 award.
- 1994-1996 Fellow, Division of Clinical Virology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama
- 1992-1994 Fellow, Division of Infectious Disease, Department of Pediatrics, University of Texas Southwestern Medical School, Dallas, Texas (supported by the NCI T32 CA09640)
- 1990-1992 Pediatric Resident, Children's Medical Center of Dallas, University of Texas Southwestern Medical School, Dallas, Texas
- 1989-1990 Pediatric Intern, Children's Medical Center of Dallas, University of Texas Southwestern Medical School, Dallas, Texas

#### **ACADEMIC APPOINTMENTS AND POSITIONS**

- 2014-present Vice Chair for Clinical and Translational Research, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama
- 2009-present Sergio Stagno Endowed Chair in Pediatric Infectious Diseases
- 2008-present Co-Director, Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama
- 2007-present Professor of Pediatrics, with tenure, Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama
- 2008 Director, University of Alabama at Birmingham Participant and Clinical Interactions Resource (PCIR) component of the UAB Clinical and Translational Science Award (CTSA)
- 2007-2008 Interim Director, University of Alabama General Clinical Research Center (GCRC), Birmingham, Alabama.

2006-2007 Associate Director, University of Alabama at Birmingham Center for Clinical and Translational Science, Birmingham, Alabama

2002-2007 Associate Professor of Pediatrics, with tenure, Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama

2002-present Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama

2001-2014 Director of Subspecialty Medical Education, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama

2001-2004 Medical Director of the Pediatric Clinical Trials Office, University of Alabama at Birmingham, Birmingham, Alabama

2001-2007 Associate Director, University of Alabama General Clinical Research Center (GCRC), Birmingham, Alabama.

1999-2002 Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama

1999-present Scientist, Center for Outcomes and Effectiveness Research and Education, University of Alabama at Birmingham, Birmingham, Alabama

1996-2002 Assistant Professor of Pediatrics, Division of Clinical Virology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama

## **AWARDS AND HONORS**

2018 Selection by physician peers for inclusion in Best Doctors in America® 2018

2017 University of Alabama at Birmingham Department of Pediatrics Excellence in Teaching Award

2017 IDWeek 2017 Program Committee Choice Award for

outstanding scientific research, given to the four best accepted abstracts overall (for blood viral load in congenital CMV, Abstract #66384)

- 2017 Chartrand Memorial Lectureship, Creighton University, Omaha, Nebraska
- 2017 Leadership Birmingham Class of 2017-2018
- 2017 Selection by physician peers for inclusion in Best Doctors in America® 2017
- 2016 University of Alabama at Birmingham Department of Pediatrics Excellence in Teaching Award
- 2016 Ronald McDonald House Charities 2016 Medical Award of Excellence
- 2016 Alabama Chapter of the American Academy of Pediatrics' 2016 Marsha Raulerson Advocacy Award
- 2016 Floyd Denny Professor Lectureship, University of North Carolina, Chapel Hill, North Carolina
- 2016 Selection by physician peers for inclusion in Best Doctors in America® 2016
- 2015 American Academy of Pediatrics Alabama Chapter Special Achievement Award for distinguished service and dedication to the mission and goals of the Academy
- 2015 Philip Porter Lecture, Harvard University and Mass General Hospital for Children, Boston, Massachusetts
- 2015 Election to American Pediatric Society (APS)
- 2015 Selection by physician peers for inclusion in Best Doctors in America® 2015
- 2014 Educational Recognition Award, University of Alabama at Birmingham Department of Pediatrics (for impact and contributions to educational endeavors of the Department)
- 2014 Election as Fellow of the Pediatric Infectious Diseases Society (FPIDS)

- 2014 Selection by Journal of Infectious Diseases of the Editorial Commentary entitled “The Scarlet H” for an Editor’s Choice award
- 2014 Lowell Glasgow Lectureship in Pediatrics, University of Utah, Salt Lake City, Utah
- 2014 Selection by physician peers for inclusion in Best Doctors in America® 2014
- 2013-2015 President, Pediatric Infectious Diseases Society
- 2013 Selection by Journal of Infectious Diseases of the paper entitled “Oseltamivir pharmacokinetics, dosing, and resistance among children aged < 2 years with influenza” for an Editor’s Choice award
- 2013 Selection by physician peers for inclusion in Best Doctors in America® 2013
- 2012 Selection by UAB Gold Humanism Honor Society third and fourth year medical students as faculty member who models the qualities of integrity, excellence, compassion, altruism, respect, and empathy in the care of patients
- 2012 Election as Fellow of the Infectious Diseases Society of America (FIDSA)
- 2012 Inaugural recipient of the Richard F Jacobs, M.D. Lectureship in Infectious Disease, Arkansas Children's Hospital / University of Arkansas for Medical Sciences, Little Rock, Arkansas
- 2012 Hugh Carithers Visiting Professor in Pediatric Infectious Diseases, University of Florida, Jacksonville
- 2011-2013 President-Elect, Pediatric Infectious Diseases Society
- 2011 Selection by UAB Gold Humanism Honor Society third and fourth year medical students as faculty member who models compassion, integrity, honor, intelligence, and excellence in clinical practice
- 2011-2012 Selection by physician peers for inclusion in Best Doctors

in America® 2011-2012

2011	Jerry Elliott Memorial Lecturer, Southeastern Association of Neonatologists
2011	Presidential Who's Who Among Business and Professional Achievers
2010	Bradford Visiting Professor, Children's Mercy Hospital, Kansas City, MO
2010	Strathmore's Who's Who Worldwide
2010	The Global Directory of Who's Who (Top Doctor), in the area of Pediatrics
2010	Selection for inclusion in Guide to America's Top Pediatricians by Consumers' Research Council of America
2009-2010	Biltmore Who's Who Among Executives and Professionals
2009	The Global Directory of Who's Who (Top Doctor), in the area of Pediatrics
2009-2010	Selection by physician peers for inclusion in Best Doctors in America® 2009-2010
2009	Argus Award nominee by third year medical students (Class of 2010) recognizing the Best Pediatrics Attending, University of Alabama at Birmingham, Department of Pediatrics
2009	Argus Award nominee by second year medical students (Class of 2011) recognizing the Best Lecturer for the Reproductive Module, University of Alabama at Birmingham
2009-2010	Marquis Who's Who in Medicine and Healthcare
2008-2009	Selection by physician peers for inclusion in Best Doctors in America® 2008-2009
2008-2009	Strathmore's Who's Who
2009	Selection for inclusion in Guide to America's Top

	Pediatricians by Consumers' Research Council of America
2008-2009	Madison Who's Who Among Executives and Professionals, Honors Edition
2008	Argus Award nominee by third year medical students (Class of 2009) recognizing the Best Pediatrics Attending, University of Alabama at Birmingham, Department of Pediatrics
2008	Selection for inclusion in Guide to America's Top Pediatricians by Consumers' Research Council of America
2008	The Global Directory of Who's Who, for contributions in the area of Pediatrics
2007	Elected to Alpha Omega Alpha, Medical Honor Society
2007-2008	Selection by physician peers for inclusion in Best Doctors in America® 2007-2008
2007	Selection for inclusion in Guide to America's Top Pediatricians by Consumers' Research Council of America
2006	Argus Award nominee by third year medical students (Class of 2007) recognizing the Best Pediatrics Attending, University of Alabama at Birmingham, Department of Pediatrics
2006-2007	Selection by physician peers for inclusion in Best Doctors in America® 2006-2007
2006-2007	Marquis Who's Who in Medicine and Healthcare
2005-2006	Selection by physician peers for inclusion in Best Doctors in America® 2005-2006
2005	Selection by the International Biographical Centre in Cambridge, England, as a member of the Leading Health Professionals of the World
2005-2006	National Register's Who's Who in Executives and Professionals
2004-2005	Selection by physician peers for inclusion in Best Doctors

in America® 2004-2005

2004-2005 Selection for inclusion in Guide to America's Top Pediatricians by Consumers' Research Council of America

2004 Who's Who in Medical Sciences Education

2003-2004 Selection by physician peers for inclusion in Best Doctors in America® 2003-2004

2003 Recipient of the Ralph E. Tiller, M.D., Distinguished Faculty Award, recognizing the faculty member that the Senior Pediatric Resident class believes has contributed the most to their overall education and training experience.

2001 Selection by the National Institute of Allergy and Infectious Diseases of the paper entitled "Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections" as one of the top 10 NIAID advances of 2001.

2000 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Program Committee Award recipient in the area of *Therapy of Microbial Diseases*

1997 International Who's Who of Professionals

1994-1996 Dixon Post-Doctoral Fellowship

1992 Who's Who Among Rising Young Americans

1986-1987 U.T. Southwestern Medical School Admissions Committee

1986 Chilton Fellowship, University of Texas Southwestern Medical School, Department of Biochemistry

1985 Southwestern Medical Foundation Merit Scholarship recipient

1985 Who's Who Among American College Students

## **MEDICAL LICENSURE**

1997-present American Board of Pediatrics – Pediatric Infectious Diseases Board Certification



1992-2016	American Board of Pediatrics – General Pediatrics Board Certification
1994-present	Alabama Medical License (#18026)
1989-1997	Texas Medical License (#H8177)

## **PROFESSIONAL SOCIETIES**

Alpha Omega Alpha, Medical Honor Society

American Academy of Pediatrics

American Pediatric Society

Association of Pediatric Program Directors

Infectious Diseases Society of America

International Society for Antiviral Research

Jefferson County Medical Society

Medical Association of the State of Alabama

Pediatric Infectious Diseases Society

Society for Pediatric Research

## **BOOK AND JOURNAL EDITOR**

Physician Editor, Interactive Grand Rounds at Medsite.com. CME program sponsored by Baylor University. Topic: Genital herpes. 2004.

Guest Editor. Updates on Herpes Viruses. *Semin. Pediatr. Infect. Dis.* 2005;16(1):1-71.\*

Associate Editor. *Red Book: Report of the Committee on Infectious Diseases.* American Academy of Pediatrics. October 2006 – June 2012. (2009 and 2012 editions)

Contributing Editor. *Nelson's Pediatric Antimicrobial Therapy.* American Academy of Pediatrics. June 2011 – present. (2012-2013 edition, 2014-2015 edition, 2015 edition, 2016 edition, 2017 edition, 2018 edition, 2019 edition)

Editor. *Red Book: Report of the Committee on Infectious Diseases.* American Academy of

Pediatrics. June 2012 – present. (2015, 2018, and 2021 editions)

### **EDITORIAL BOARDS**

Editorial Advisory Board, Infectious Diseases in Children, April 2003 – August 2012.

Editorial Board, Antiviral Research, June 2005 – January 2012.

Editorial Advisory Board, Journal of Infectious Diseases, March 2006 – August 2012.

Editorial Board, Pediatric Infectious Diseases Journal, July 2008 – August 2012.

Editorial Advisory Board, Medscape From WebMD CME Infectious Diseases, November 2009 – August 2012.

### **REVIEWER FOR MEDICAL JOURNALS (partial listing)**

Antiviral Research

Archives of Disease in Childhood

British Medical Journal

Clinical Infectious Diseases

European Journal of Pediatrics

Expert Opinion on Pharmacotherapy

Expert Review of Anti-infective Therapy

Expert Review of Molecular Diagnostics

Expert Review of Pharmacoeconomics and Outcomes Research

HERPES

Infections in Medicine

JAMA (Journal of the American Medical Association)

Journal of Clinical Virology

Journal of Infectious Diseases

Journal of Medical Virology

Journal of NeuroVirology

Journal of Pediatric Gastroenterology and Nutrition

Journal of the Pediatric Infectious Diseases Society

Journal of Pediatric Neurology

Journal of Pediatrics

Journal of Virology

Molecular Diagnosis

Nature Reviews

New England Journal of Medicine

Paediatric Drugs

Pediatric Infectious Disease Journal

Pediatrics

PLoS ONE

Scandinavian Journal of Infectious Diseases

Sexually Transmitted Diseases

Southern Medical Journal

The Lancet Infectious Diseases

The Medical Letter

Virology

Virology Journal

## **EDUCATIONAL PROGRAMS**

1. Director of the UAB Pittman GCRC Resident Clinical Research Rotation, September

2001 - April 2006.

2. Faculty mentor, University of Alabama School of Medicine Mentor Program for first year through fourth year medical students, October 2004 - July 2009.
3. Mentor, Society for Pediatric Research Young Investigator Coaching Program, April 28, 2012 - April 27, 2014. Mentee: Sallie Permar, MD, PhD (Assistant Professor of Pediatrics, Division of Pediatric Infectious Diseases, Duke University Medical Center).
4. Member, UAB Clinical Investigator Training Program (CITP) Core Faculty, 2017 - present.

### **UNIVERSITY AND DEPARTMENTAL COMMITTEES**

1. Permanent alternate member, Information Technology Advisory Group (ITAG), The University of Alabama at Birmingham Health System, September 1997 - 2000.
2. Member, Steering Committee of the Office of Clinical Research, The University of Alabama at Birmingham, October 1997 - 2001.
3. Member, Information Technology Committee, Department of Pediatrics, The University of Alabama at Birmingham, October 1997 - 2001.
4. Member, Dean's Advisory Committee for Patient-Oriented Research, The University of Alabama at Birmingham, March 1998 – February 2001.
5. Member, Pharmacy and Therapeutics Committee, The Children's Hospital of Alabama, October 1998 – December 2008.
6. Member, Conflict of Interest Task Force, Department of Pediatrics, The University of Alabama at Birmingham, July 2000 – March 2002.
7. Member, University of Alabama General Clinical Research Center Scientific Advisory Committee, October 2000 - May 2008.
8. Associate Director, University of Alabama General Clinical Research Center Medical Student Research Program, February 2001 - May 2008.
9. Faculty Mentor, University of Alabama Medical Student Research Society, February 2001 – May 2008.
10. Member, Clinical Research Advisory Group (CRAG), University of Alabama at Birmingham School of Medicine, February 2001 - April 2007.
11. Member, Recruitment and Retention Shared Facility Steering Committee, University of

- Alabama at Birmingham, 2001 – 2007.
12. Chair, Subcommittee for Patient Recruitment for Pharmaceutical Studies, Clinical Research Advisory Group, University of Alabama at Birmingham, June 2001 – July 2001.
  13. Member, Pediatric Residency Curriculum Committee, University of Alabama at Birmingham, August 2001 – present.
  14. Member, Dean’s Council for Graduate Medical Education, University of Alabama at Birmingham, October 2001 – September 2004.
  15. Member, K12 Training Grant Executive Committee, University of Alabama at Birmingham, February 2002 - June 2008.
  16. Chairman, Pharmacy and Therapeutics Antimicrobial Subcommittee, The Children’s Hospital of Alabama, February 2002 - October 2008.
  17. Member, Department of Pediatrics Privacy Working Group for HIPAA Compliance, University of Alabama at Birmingham, 2002 – 2004.
  18. Member, University of Alabama at Birmingham Clinical Research Infrastructure Steering Committee, University of Alabama at Birmingham, 2003 – 2007.
  19. Member, University of Alabama at Birmingham Human Studies Advisory Committee (H-SAC) to advise the Associate Provost for Research, University of Alabama at Birmingham, March 2003 – February 2006.
  20. Member, Department of Pediatrics Information Technology Advisory Group, University of Alabama at Birmingham, 2003 - 2006.
  21. Member, University of Alabama at Birmingham Clinical Research Infrastructure Advisory and Users Group, University of Alabama at Birmingham, 2003 - 2006.
  22. Member, Council of Postdoctoral Education, University of Alabama at Birmingham, October 2003 – 2007.
  23. Chairman, Search Committee for Director of Biostatistics for the NIAID Collaborative Antiviral Study Group, Medical Statistics Section, Department of Medicine, University of Alabama at Birmingham, 2004 - 2006.
  24. Member, University of Alabama at Birmingham Office for Human Research Working Group, University of Alabama at Birmingham, 2005 - 2007.
  25. Member, Children’s Hospital of Alabama Physician Communications Committee, 2005 –

- 2010.
26. Member, State Advisory Committee for the Pediatric Pulmonary Center at the University of Alabama at Birmingham (funded by the Maternal and Child Health Bureau/HRSA), July 2005 - present.
  27. Member, Search Committee for Director of Inpatient Services at Children's Hospital of Alabama, University of Alabama at Birmingham, 2008 - 2010.
  28. Member, UAB Southeast Biosafety Laboratory Alabama Birmingham (SEBLAB) Emergency Response Advisory Group, July 2009 - present.
  29. Member, Children's Health System Periodic Performance Review Team / Infection Control MRSA Policy Committee, 2009 - 2011.
  30. Member, Hospital Medicine Inpatient Services Oversight Committee, Children's Hospital of Alabama and University of Alabama at Birmingham, 2010 - 2014.
  31. Principal Investigator, Children's Health System Infection Control Communal Equipment Review Committee (wagon study), 2010 - 2011.
  32. Member, Children's Health System Documentation Improvement and Coding Acuity Work Group, 2010 - 2013.
  33. Member, Pediatric Gastroenterology Division Director Search Committee, 2010.
  34. Co-Sponsor and Team Director, Children's Health System iConnect Electronic Medical Record Physician Documentation Project Team, 2010 - 2012.
  35. Member, UAB Information Security Advisory Committee (formerly the President's Security Forum), 2013 - present.
  36. Member, Search Committee for Chair of the Department of Pediatrics, University of Alabama at Birmingham, 2013 - 2014.
  37. Member, Committee on Academics for the Department of Pediatrics (advises the Vice Chair of Academics for the department), University of Alabama at Birmingham, 2014.
  38. Member, 2014 Strategic Planning Work Group for Children's of Alabama, dealing with national and state healthcare system issues, 2014 - present.
  39. Member, Southeastern Regional Pediatric Disaster Surge Network (SRPDSN) Table Top Exercise planning committee, December 2014 - May 2015. Exercise held on May 7, 2015.

40. Elected Member, University of Alabama at Birmingham Faculty Council (reviews and evaluates individual faculty members proposed for appointment, promotion, and/or tenure award, making recommendations to the Dean as appropriate), 2015 - 2016.
41. Member, University of Alabama at Birmingham Clinical Trials Office Faculty Research Education Advisory Workgroup, 2015 - present.
42. Member, University of Alabama at Birmingham School of Medicine AMC21 Executive Research Steering Committee, 2015 - present.
43. Member, University of Alabama at Birmingham School of Medicine AMC21 Reload Pillar “Inflammation, Infection, and Immunity (I3)” Steering Committee, 2016 - present.
44. Chair, University of Alabama at Birmingham Faculty Council (reviews and evaluates individual faculty members proposed for appointment, promotion, and/or tenure award, making recommendations to the Dean as appropriate), 2016 - 2019.
45. Chair, University of Alabama at Birmingham Department of Pediatrics Search Committee for Adolescent Medicine Division Director, 2016-2017.
46. Member, University of Alabama at Birmingham Department of Pediatrics Search Committee for General Pediatrics Division Director, 2016-2017.
47. Member, Advisory Committee for the University of Alabama at Birmingham Center for Clinical and Translational Science (CCTS), 2017 - present.

#### **COMMITTEES FOR PROFESSIONAL SOCIETIES AND NATIONAL ORGANIZATIONS**

1. Member, Pediatric Infectious Diseases Society Fellowship Awards Committee, May 2001 - May 2004.
2. Member, 2004 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting Subspecialty Abstract Review Committee.
3. Moderator, Neonatal Infectious Diseases – Nosocomial Infections: Challenges and Solutions Slide Session, 2004 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, San Francisco, California, May 1, 2004.
4. Member, Pediatric Infectious Diseases Society Nominations and Awards Committee, 2004 - 2006 (elected office).
5. Virology expert consultant to the State of North Carolina Department of Health and Human Services, in support of North Carolina public health preparedness for a public health emergency, 2005 – present.

6. Section Member, American Academy of Pediatrics Committee on Infectious Diseases (the Red Book Committee), representing the American Academy of Pediatrics Section on Infectious Diseases, 2005 - 2006.
7. Committee Member, American Academy of Pediatrics Committee on Infectious Diseases (the Red Book Committee), 2006 - 2011.
8. Member, Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) Varicella Working Group (AAP COID liaison), February 2006 – July 2006.
9. Member, 2006 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting Subspecialty Abstract Review Committee.
10. Moderator (with Sheldon Kaplan, M.D.), Infectious Diseases I Slide Session, 2006 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, San Francisco, California, April 30, 2006.
11. Member, Pediatric Infectious Diseases Society Council, 2006 - 2010.
12. American Academy of Pediatrics Committee on Infectious Diseases liaison to the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP), August 2006 – present.
13. Member, Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) Use of Vaccines During Pregnancy Working Group (AAP COID liaison), October 2006 – March 2008.
14. Co-Chairperson, Pediatric Infectious Diseases Society Program and Meetings Committee, 2006 – 2011.
15. Member, Infectious Diseases of America (IDSA) Program Planning Committee (PIDS liaison), 2007 – 2011.
16. Member, Herpesvirus Working Group, Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Persons, January 2007 – July 2008. Guidelines published online at <http://www.aidsinfo.nih.gov/> June 18, 2008, and in MMWR.
17. Member, Pediatric Working Group, Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and -Infected Children, February 2007 – July 2008. Guidelines published online at <http://www.aidsinfo.nih.gov/>



June 20, 2008, and in MMWR.

18. Leader, Cytomegalovirus section of Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and -Infected Children, February 2007 – June 2007.
19. Moderator, Infectious Diseases II – Advances in Virology Platform Session, 2008 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Honolulu, Hawaii, May 4, 2008.
20. Member, Pediatric Infectious Diseases Society Education and Research Foundation Board of Trustees, 2008 – 2010.
21. Member, Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) MMRV Vaccine Safety Working Group (AAP COID liaison), May 2008 – June 2009.
22. Member, Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) Anthrax Working Group (AAP COID liaison), May 2008 – present.
23. Member, National Center for Research Resources (NCRR/NIH) Clinical and Translational Science Awards PCIR Workgroup Taskforce, June 2008 – August 2008.
24. Moderator, Communicating Infectious Diseases and Vaccine Issues to the Public, 48<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / 46<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Washington D.C., October 27, 2008.
25. Moderator, Vexing Viruses in Children and Adolescents, 48<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / 46<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Washington D.C., October 28, 2008.
26. Scientific representative for Children’s Hospital of Alabama to the National Pediatric Research Consortia, Congressional Advocacy Day, Washington D.C., February 3-4, 2009.
27. Moderator, How Can We Better Communicate Vaccine Issues With the Public? 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 30, 2009.
28. Moderator, Hot Topics in Pediatric Infectious Diseases, 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 30, 2009.

29. Moderator, Pediatrics Oral Abstract Session, 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 31, 2009.
30. Member, Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) Respiratory Syncytial Virus Passive Immunotherapy Working Group (AAP COID liaison), August 2009 – November 2010.
31. Member, Project Advisory Committee directing the American Academy of Pediatrics' Childhood Immunization Support Program (CISP), supported by a grant from the U.S. Department of Health and Human Services Center for Disease Control and Prevention, February 2010 – September 2014.
32. Scientific representative for Children's Hospital of Alabama to the National Pediatric Research Consortia, Congressional Advocacy Day, Washington D.C., April 13-14, 2010.
33. Member, Pediatric Infectious Diseases Society Communications Committee, 2010 – 2013.
34. Course Director, Infectious Diseases in Children Annual Symposium, 2010 – present.
35. Moderator, Meet the Red Book, 48<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, October 21, 2010, and October 23, 2010.
36. Moderator, Update on Pneumonia: Etiology and Management, 48<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, October 23, 2010.
37. Moderator, Hot Topics in Pediatric Infectious Diseases, 48<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, October 24, 2010.
38. Member, Cytomegalovirus Disease Subject Working Group, Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Persons, June 2010 – October 2013.
39. Member, Non-CMV Herpes Disease Subject Working Group, Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Persons, June 2010 – October 2013.
40. Member, Pediatric Infectious Diseases Society Education and Research Foundation (PIDSERF) Fellowship Development Committee, October 2010 – present.

41. Member, Pediatric Working Group, Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and -Infected Children, November 2010 – present.
42. Member, Centers for Disease Control and Prevention (CDC) Respiratory Syncytial Virus Passive Immunotherapy Working Group (AAP COID liaison), January 2011 – February 2012.
43. President-Elect, Pediatric Infectious Diseases Society, May 2011 – April 2013.
44. Program Chair, IDWeek 2012 Program Planning Committee (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), 2011-2012.
45. Member, Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) Japanese Encephalitis Vaccine Safety Working Group (AAP COID liaison), May 2012 – October 2012.
46. President, Pediatric Infectious Diseases Society, May 2013 – April 2015.
47. Moderator, Encephalitis and Encephalopathy on Both Coasts of the Pacific Ocean, Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Washington D.C., May 5, 2013.
48. Moderator, Evidence-Based Approach to Countering Vaccine Hesitancy, Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Washington D.C., May 6, 2013.
49. Member, Herpesvirus Working Group, Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents, October 2013 – October 2017.
50. Past-President, Pediatric Infectious Diseases Society, May 2015 – April 2017.
51. Pediatric Infectious Diseases Society Liaison to Infectious Diseases Society of America Board of Directors, May 2015 – April 2017.
52. Chair, Pediatric Infectious Diseases Society Nominations and Awards Committee, 2015 - 2017.
53. Member, Pediatric Infectious Diseases Society Fellowship Awards Committee, 2015 - 2017.

54. Member, Pediatric Infectious Diseases Society International Affairs Committee, 2015 - 2017.
55. Moderator, Emerging Paradigms: Pediatric Viral Infections, IDWeek 2017 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Diego, California, October 6, 2017.
56. Member, Alabama Vaccine Advisory Committee (joint initiative of the Alabama Chapter of the American Academy of Pediatrics, the Alabama Department of Public Health, and the Alabama Academy of Family Physicians), 2017-present.

### **COMMITTEES FOR NATIONAL AND INTERNATIONAL MEETINGS**

1. Rappateur, Consensus Symposium on Antiviral Resistance. Sponsored by: International Society for Antiviral Research, and National Institute of Allergy and Infectious Diseases. Hamilton, Bermuda, December, 1994.
2. Rappateur, National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group (CASG) Neonatal Herpes Simplex Virus working group. NIAID CASG Annual Meeting, Bethesda, Maryland, March, 1996.
3. Discussant, Management of Herpesvirus Infections in the Immunocompromised Host With and Without HIV Infection. 4<sup>th</sup> Annual Meeting of the International Herpes Management Forum (IHMF), Barcelona, Spain, November, 1996.
4. Rappateur, NIAID CASG Neonatal Working Group: Suppressive oral acyclovir therapy following neonatal herpes simplex virus disease. NIAID CASG Annual Meeting, Bethesda, Maryland, March, 1997.
5. Consultant, Centers for Disease Control and Prevention Genital Herpes Prevention Project. Atlanta, Georgia, May 5-6, 1998. From the CDC: Prevention Agenda for Genital Herpes. Sexually Transmitted Diseases (journal).
6. Moderator, Lymphotropic Herpesvirus Slide Session, 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada; September 19, 2000.
7. Chairperson, From Basic To Clinical Science session, 18<sup>th</sup> International Union Against Sexually Transmitted Diseases (IUSTI) Europe Congress on Sexually Transmitted Diseases, Vienna, Austria, September 13, 2002.
8. Chairperson, United States Regional Guideline Discussion, International Herpes Management Forum (IHMF) 10<sup>th</sup> Annual Meeting, Paris, France, February 28, 2003.

9. Chairperson, Respiratory and West Nile Viruses session, 18<sup>th</sup> International Conference on Antiviral Research (ICAR), Barcelona, Spain, April 13, 2005.
10. International Program Scientific Committee for the 2<sup>nd</sup> Dominique Dormont International Conference on Pathogenesis of Prion and Viral Infections, Paris, France, December 1-3, 2005.
11. American Academy of Pediatrics representative to the Council of State and Territorial Epidemiologists (CSTE) / Centers for Disease Control and Prevention (CDC) Consultation on Neonatal Herpes Surveillance, Atlanta, Georgia, March 20-21, 2007.
12. Session leader, Centers for Disease Control and Prevention (CDC) Congenital Cytomegalovirus Conference: Public Health Action Towards Awareness, Prevention, and Treatment, Atlanta, Georgia, November 5-7, 2008.
13. Course Director, 23<sup>rd</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 20-21, 2010.
14. Member, Scientific Committee, 5<sup>th</sup> International Meeting on Neonatal Infectious Diseases, Pavia, Italy, May 19-20, 2011.
15. Chairperson, Cutting Edge Issues in Pediatric Infectious Diseases session, European Society of Pediatric Infectious Diseases (ESPID) 2011 World Forum, The Hague, The Netherlands, June 10, 2011.
16. Course Director, 24<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 19-20, 2011.
17. Program Chair, IDWeek 2012 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), October 2012.
18. Moderator, Emerging Infections in Children oral abstract session, IDWeek / 50<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Diego, California, October 18, 2012.
19. Moderator, Maxwell Finland Lecture, IDWeek / 50<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Diego, California, October 18, 2012. Recipient: George McCracken.
20. Moderator, Late Breaker oral abstract session, IDWeek / 50<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Diego, California, October 18, 2012.
21. Moderator, Closing Plenary, IDWeek / 50<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Diego, California, October 21, 2012. Vaccine-

preventable diseases: Optimizing health benefits.

22. Course Director, 25<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 17-18, 2012.
23. Course Director, 26<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 16-17, 2013.
24. Member, Scientific Committee, 32<sup>nd</sup> Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID), Dublin, Ireland, May 6-10, 2014.
25. Moderator, 32<sup>nd</sup> Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID) / Pediatric Infectious Diseases Society (PIDS) Joint Symposium on Viral Infections, Dublin, Ireland, May 8, 2014.
26. Course Director, 27<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 22-23, 2014.
27. Member, Congenital CMV Diagnosis, Prevention, and Treatment Consensus Meeting, Brisbane, Australia, April 19, 2015. One of 22 international experts invited to plan and participate in this meeting.
28. Moderator, PIDS Caroline B. Hall Lectureship, IDWeek 2015 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Diego, California, October 8, 2015.
29. Moderator, Late Breaker oral abstract session, IDWeek 2015 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Diego, California, October 9, 2015.
30. Chair, Pediatric Infectious Diseases Symposium at the 9<sup>th</sup> World Congress of Pediatric Infectious Diseases, Rio de Janeiro, Brazil, November 19, 2015. Challenges in Perinatal Infections.
31. Course Director, 28<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 21-22, 2015.
32. Member, Scientific Committee, 7<sup>th</sup> International Meeting on Neonatal Infectious Diseases, Pavia, Italy, June 9-10, 2016.
33. Course Director, 29<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 19-20, 2016.

34. Ex officio member, Immunization Advisory Committee for Alabama, Alabama Department of Public Health, August 2017 - present.
35. Course Director, 30<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 18-19, 2017.
36. Member, Organizing Committee for the 7<sup>th</sup> International Congenital CMV Conference & 17<sup>th</sup> International CMV/Betaherpesvirus Workshop, Birmingham, Alabama, April 7-11, 2019.

#### **NIH COMMITTEES, MEETINGS, AND SITE VISITS**

1. National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group (CASG) Neonatal Sub-Committee Meeting, Birmingham, Alabama, October 12, 1994.
2. NIAID CASG Annual Meeting, Bethesda, Maryland, November 29 - December 1, 1994.
3. NIAID Division of Microbiology and Infectious Diseases (DMID) Clinical Antiviral Research Program Review, Rockville, Maryland, January 11, 1995.
4. NIAID CASG Advisory Committee, 1995-1996.
5. NIAID CASG Pediatric Herpes Simplex Virus Subcommittee, 1995-1996.
6. NIAID CASG Pediatric Cytomegalovirus Subcommittee, 1995-1996.
7. NIAID CASG Annual Meeting, Bethesda, Maryland, March 13 - March 15, 1996.
8. NIAID CASG Advisory Committee, 1996-1997.
9. NIAID CASG Pediatric Herpes Simplex Virus Subcommittee, 1996-1997.
10. NIAID CASG Pediatric Cytomegalovirus Subcommittee, 1996-1997.
11. NIAID CASG Pediatric Human Papillomavirus Subcommittee, 1996-1997.
12. NIAID CASG Neonatal Sub-Committee Meeting, Washington D.C., May 8, 1996.
13. NIAID CASG Laryngeal Papillomatosis Sub-Committee Meeting, Cincinnati, Ohio, December 7, 1996.
14. NIAID CASG Annual Meeting, Bethesda, Maryland, March 12 - March 14, 1997.
15. NIAID CASG Advisory Committee, 1997-1998.

16. NIAID CASG Pediatric Herpes Simplex Virus Subcommittee, 1997-1998.
17. NIAID CASG Pediatric Cytomegalovirus Subcommittee, 1997-1998.
18. NIAID CASG Pediatric Human Papillomavirus Subcommittee, 1997-1998.
19. NIAID CASG Pediatric Enterovirus Subcommittee, 1997-1998.
20. NIH National Cancer Institute site visit, Frederick, Maryland, May 5, 1997.
21. NIAID CASG Start-up Meeting: Placebo-Controlled Phase III Evaluations of Suppressive Therapy with Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections 1) Limited to the Skin, Eyes, or Mouth, or 2) Involving the Central Nervous System, Dallas, Texas, June 26, 1997.
22. NIAID CASG Start-up Meeting: A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children, Dallas, Texas, September 12, 1997.
23. NIAID CASG Annual Meeting, Bethesda, Maryland, February 18-20, 1998.
24. Chair, National Institutes of Health (NIH) Women and Infants Transmission Study Group (WITS) Human Herpesvirus-6 (HHV-6) Working Group, March 1998 – August 2001.
25. NIAID CASG Advisory Committee, 1998-1999.
26. NIAID CASG Pediatric Herpes Simplex Virus Subcommittee, 1998-1999.
27. NIAID CASG Pediatric Cytomegalovirus Subcommittee, 1998-1999.
28. NIAID CASG Pediatric Human Papillomavirus Subcommittee, 1998-1999.
29. NIAID CASG Pediatric Enterovirus Subcommittee, 1998-1999.
30. NIAID CASG Pediatric Hepatitis C Subcommittee, 1998-1999.
31. NIAID CASG Enterovirus Sub-Committee Meeting, Washington D.C., February 9, 1999.
32. NIAID CASG Annual Meeting, Bethesda, Maryland, February 17-19, 1999.
33. NIAID CASG Start-up Meeting: A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children, Dallas, Texas, March 12, 1999.
34. NIAID CASG Start-Up Meeting: A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial Of Pleconaril (VP 63843) In The Treatment Of Infants With Enteroviral



- Meningitis, Kansas City, MO, May 14, 1999.
35. NIAID CASG Start-Up Meeting: A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (VP63843) In The Treatment Of Neonates With Enteroviral Sepsis Syndrome, Kansas City, MO, May 14, 1999.
  36. NIAID CASG Advisory Committee, 1999-2000.
  37. NIAID CASG Pediatric Herpesvirus Subcommittee, 1999-2000.
  38. NIAID CASG Pediatric Human Papillomavirus Subcommittee, 1999-2000.
  39. NIAID CASG Pediatric Enterovirus Subcommittee, 1999-2000.
  40. NIAID CASG Annual Meeting, Bethesda, Maryland, February 23-25, 2000.
  41. NIAID CASG Advisory Committee, 2000-2001.
  42. NIAID CASG Pediatric Herpesvirus Subcommittee, 2000-2001.
  43. NIAID CASG Pediatric Enterovirus Subcommittee, 2000-2001.
  44. NIAID CASG Annual Meeting, Bethesda, Maryland, February 14-16, 2001.
  45. NIAID CASG Advisory Committee, 2001-2002.
  46. NIAID CASG Pediatric Herpesvirus Subcommittee, 2001-2002.
  47. NIAID CASG Pediatric Enterovirus Subcommittee, 2001-2002.
  48. NIAID CASG Start-up Meeting: A Phase I/II Pharmacokinetic and Pharmacodynamic Evaluation of Oral Valganciclovir in Neonates with Symptomatic Congenital Cytomegalovirus (CMV) Infection Involving the Central Nervous System (CASG Protocol #109), Houston, Texas, December 3, 2001.
  49. NIAID CASG Leadership Retreat, Baltimore, Maryland, January 22-23, 2002.
  50. NIAID CASG Annual Meeting, Bethesda, Maryland, February 20-22, 2002.
  51. NIAID CASG Advisory Committee, 2002-2003.
  52. NIAID CASG Pediatric Herpesvirus Subcommittee, 2002-2003.
  53. NIAID CASG Pediatric Enterovirus Subcommittee, 2002-2003.

54. NIDCD/NIH Workshop “Congenital Cytomegalovirus Infection and Hearing Loss,” Rockville, MD, March 19-20, 2002.
55. NIAID CASG Annual Meeting, Bethesda, Maryland, February 19-21, 2003.
56. NIAID CASG Advisory Committee, 2003-2004.
57. NIAID CASG Pediatric Herpesvirus Subcommittee, 2003-2004.
58. NIAID CASG Pediatric Enterovirus Subcommittee, 2003-2004.
59. NIAID CASG Annual Meeting, Bethesda, Maryland, February 18-20, 2004.
60. NIAID CASG Advisory Committee, 2004-2005.
61. NIAID CASG Pediatric Herpesvirus Subcommittee, 2004-2005.
62. NIAID CASG Pediatric Enterovirus Subcommittee, 2004-2005.
63. NIAID CASG Annual Meeting, Bethesda, Maryland, February 23-25, 2005.
64. NIAID CASG Annual Meeting, Bethesda, Maryland, February 22-24, 2006.
65. NIAID CASG Annual Meeting, Bethesda, Maryland, February 21-23, 2007.
66. Member, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 05-0077 entitled "CS-8958 - A Phase 1, double-blind, placebo-controlled, ascending single inhaled dose, safety, tolerability and pharmacokinetic study in healthy subjects," 2007-2008.
67. NIAID CASG Annual Meeting, Bethesda, Maryland, February 20-22, 2008.
68. Chairman, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 05-0077 entitled "CS-8958 – A Phase 1, double-blind, placebo-controlled, ascending single inhaled dose, safety, tolerability and pharmacokinetic study in healthy subjects," 2008.
69. Chairman, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 07-0064 entitled “CS-8958 – A Phase I, double-blind, placebo controlled, ascending single inhaled dose, safety, tolerability and pharmacokinetic study in elderly subjects,” 2008-2009.
70. Chairman, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 04-039 entitled “A randomized, double-blind, placebo-controlled, Phase II study to assess the safety and efficacy of the cytomegalovirus gB/MF59 vaccine in preventing

- systemic cytomegalovirus infection in healthy adolescent females,” 2008-2014.
71. Chairman, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 08-0002 entitled “CS-8958 – A Phase I, double-blind, placebo controlled, ascending, multiple dose, safety, tolerability and pharmacokinetic study in healthy subjects,” 2008-2009.
  72. NIAID CASG Annual Meeting, Bethesda, Maryland, February 18-20, 2009.
  73. Invited presenter and participant, NIAID Influenza Antiviral Development Workshop. “Oseltamivir in Infants – Collaborative Antiviral Study Group (CASG)”, Bethesda, MD, March 26, 2009.
  74. Invited consultant, NIAID Consultation with the Outside Community on Developing Clinical Research Infrastructure for Infectious Diseases: 2010-2020, Bethesda, MD, July 9-10, 2009.
  75. Member, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 09-0005 [A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Inactivated Trivalent Influenza Vaccine in Healthy Pregnant Women], 2009-2014.
  76. Member, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 09-0007 [Randomized, Single-Blinded Comparison of Safety and Immunogenicity of Live Attenuated Influenza Vaccine (LAIV) with Trivalent Inactivated Vaccine (TIV) in Post-Partum Nursing Women], 2009-2014.
  77. Member, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 09-0018 [Comparison of Increased Dose(s) (0.5 ml) of Trivalent Inactivate Influenza Vaccine (TIV) with Standard Dose(s) (0.25 ml) TIV in children 6-35 months of age], 2009-2014.
  78. Member, NIAID Data and Safety Monitoring Board (DSMB) for DMID Protocol Number 10-0076 [A Phase II Study in Adults with Rheumatoid Arthritis receiving TNF-Alpha-Inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels], 2011-2014.
  79. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0039 [Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Healthy Adult and Elderly Populations], 2009-2011.
  80. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0043 [A Phase II Study in

- Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted CSL H1N1 Influenza Vaccine Administered at Two Dose Levels], 2009-2011.
81. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0047 [Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Previously Primed Infants and Toddlers ( $\geq 6 - < 36$  months), Children ( $\geq 36$  months – 9 years), and Adolescents (10 – 17 years)], 2009-2011.
  82. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0053 [A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels], 2009-2011.
  83. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0054 [A Phase II Study in Infants ( $\geq 6 - < 36$  months), Children ( $\geq 36$  months – 9 years), and Adolescents (10 – 17 years) to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered in Two Dose Levels], 2009-2011.
  84. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0056 [A Phase II Study in Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels], 2009-2011.
  85. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0058 [A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a Sanofi Pasteur H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant], 2009-2011.
  86. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0072 [A Phase II Study in Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels], 2009-2011.
  87. Member and Back-up Chair, NIAID Data and Safety Monitoring Board (DSMB) for DMID studies of novel H1N1 vaccines, Protocol Number 09-0073 [A Phase II Study in HIV-seropositive Adults to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels], 2009-2011.

88. Ad Hoc Member, NIAID Intramural Data and Safety Monitoring Board (DSMB) for NIAID Protocol entitled “A Randomized Open Label Phase 2, Safety and Exploratory Efficacy of Investigational anti-H1N1 Influenza A Immune Plasma for the Treatment of Novel H1N1 Influenza,” 2009-2018.
89. NIAID CASG Annual Meeting, Bethesda, Maryland, February 17-19, 2010.
90. Member, Centers for Disease Control and Prevention (CDC) Data and Safety Monitoring Board (DSMB) for Protocol Number 062-03-2012 [Efficacy of early oseltamivir phosphate treatment at hospital admission to reduce severity of illness among children aged less than 10 years hospitalized with influenza in El Salvador and Panama], 2012-2013.
91. Member, NIAID Safety Monitoring Committee (SMC) for DMID Protocol Number 14-0052 [A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Assessment of the Safety and Antiviral Activity of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Normal Healthy Adult Volunteers who are Experimentally Infected with a Challenge Strain of Influenza A Virus], 2015-2018.
92. Member, NIAID Safety Monitoring Committee (SMC) for DMID Protocol Number 16-0033 [Phase 1, Double-blinded, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability, and Immunogenicity of Inactivated Adjuvanted Zika Virus (ZIKV) Vaccine Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects], 2016-present.
93. Member, NIAID Safety Monitoring Committee (SMC) for DMID Protocol Number 16-0062 [A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) with Alum Adjuvant in Healthy Flavivirus-naïve and Flavivirus-Primed Subjects], 2016-present.
94. Member, NIAID Safety Monitoring Committee (SMC) for DMID Protocol Number 16-0034 [Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area], 2016-present.
95. Member, Beth Israel Deaconess Medical Center (BIDMC) Safety Monitoring Committee (SMC) for the Walter Reed Army Institute of Research (WRAIR) and Vaccine Research Center/National Institute of Allergy and Infectious Diseases (VRC/NIAID) Z001 trial [A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule with a Zika Virus Purified Inactivated Vaccine plus Alum Adjuvant in Healthy Adults], 2016-present.
96. Member, External Advisory Committee, Mississippi Pediatric Clinical Trials Center of the IDeA States Pediatric Clinical Trials Network (ISPCTN), National Institute of General Medical Sciences, NIH, 2016-present.

97. Speaker and participant, NIAID Workshop on Zika Virus Therapeutics, Rockville, MD, September 6-7, 2017. Lessons learned: CMV, HSV, influenza.

### **FDA COMMITTEES**

1. Member, FDA Office of Orphan Products Development Grants Panel, Washington, D.C., June 5, 2003.
2. Member, FDA Pediatric Advisory Committee, Influenza Antiviral Therapeutics Meeting, Washington, D.C., November 27, 2007.
3. Member, FDA Microbiology Devices Panel of the Medical Devices Advisory Committee, September 29, 2017, through February 28, 2021.

### **FOUNDATION COMMITTEES**

1. Member, Thrasher Research Fund Grand Review Panel, Salt Lake City, Utah, June 23, 2017.

### **CONGRESSIONAL TESTIMONY**

1. Testimony before the United States Senate Special Committee on Aging: Sudden Price Spikes in Off-Patent Drugs: Perspectives from the Front Lines. Washington, D.C., December 9, 2015.

### **ORAL PRESENTATIONS AT SCIENTIFIC MEETINGS**

1. 35<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, September, 1995. Application of the polymerase chain reaction (PCR) to the diagnosis and management of neonatal herpes simplex virus (HSV) disease.
2. 6<sup>th</sup> International Cytomegalovirus Workshop, Perdido Beach Resort, Orange Beach, Alabama, March 9, 1997. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study.
3. Society for Pediatric Research (SPR), San Francisco, California, May 4, 1999. The safety and efficacy of high-dose acyclovir in neonatal herpes simplex virus infections.
4. 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada, September 19, 2000. Ganciclovir (GCV) Treatment of Symptomatic Congenital Cytomegalovirus (CMV) Infections: Results of a Phase III Randomized Trial. (Recipient of the 2000 ICAAC Program Committee Award in the area of *Therapy of Microbial Diseases*).

5. 8<sup>th</sup> International Cytomegalovirus Workshop, Asilomar Conference Grounds, Pacific Grove, Monterey Peninsula, California, May 23, 2001. Ganciclovir Therapy for Congenital Cytomegalovirus Disease: Results of a Phase III Randomized Study.
6. Centers for Disease Control and Prevention (CDC) Congenital Cytomegalovirus Conference: Public Health Action Towards Awareness, Prevention, and Treatment, Atlanta, Georgia, November 5-7, 2008. Benefits and risks of current antiviral treatments for children with congenital CMV.
7. 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 31, 2009. Oseltamivir (OST) and OST Carboxylate (CBX) Pharmacokinetics (PK) in Infants: Interim Results from a Multicenter Trial.
8. 48<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, October 22, 2010. Impact of oral acyclovir suppression on neurodevelopmental outcomes and skin recurrences following neonatal herpes simplex virus disease.
9. IDWeek 2013 (annual meeting of the Pediatric Infectious Diseases Society, the Infectious Diseases Society of America, the HIV Medical Association, and the Society for Healthcare Epidemiology of America), San Francisco, CA, October 5, 2013. Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: Results of a Phase III, randomized, double-blind, placebo-controlled, multinational study.

#### **POSTER PRESENTATIONS AT SCIENTIFIC MEETINGS**

1. Infectious Disease Society of America (IDSA), Orlando, Florida, 1994. Mechanism of dexamethasone action in bacterial meningitis: dexamethasone (DXM) destabilizes interleukin-1 $\beta$  mRNA in the human astrocytoma cell line U-373MG.
2. International Herpes Management Forum (IHMF), San Francisco, California, 1994. Neonatal characteristics of infants born to women shedding herpes simplex virus (HSV) proximate to delivery.
3. Society for Pediatric Research (SPR), San Diego, California, 1995. Maternal and neonatal effects of genital herpes simplex virus (HSV) shedding proximate to delivery.
4. 42<sup>nd</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Boston, MA; October 2, 2004. Serum Polymerase Chain Reaction (PCR) May Not Diagnose Neonatal Herpes Simplex Virus (HSV) Disease.

#### **INVITED ORAL LECTURES AT NATIONAL MEETINGS, INTERNATIONAL MEETINGS, AND OTHER UNIVERSITIES**

1. National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group (CASG) Annual Meeting, Bethesda, Maryland, November, 1994. Characteristics of neonates exposed to herpes simplex virus at delivery: implications for disease prevention.
2. Louisiana State University Baton Rouge Pediatric Grand Rounds, Baton Rouge, Louisiana, November, 1995. The use of antiviral agents in clinical pediatric practice.
3. National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group (CASG) Annual Meeting, Bethesda, Maryland, March, 1996. a) Oral acyclovir suppressive therapy following neonatal herpes simplex virus (HSV) disease. b) Utilization of the polymerase chain reaction (PCR) in the management of neonatal HSV infections.
4. Journee Annuelle de Neonatalogie 1996, Rocourt, Belgium, June 8, 1996. The diagnosis, management, and prevention of neonatal herpes simplex virus disease.
5. Pfizer Viral Symposia, Groton, Connecticut, September, 1996. Current and emerging therapy for viral infections: Where are therapeutic approaches inadequate?
6. National Institute of Health (Japan), Tokyo, Japan, February 25, 1997. Human herpesvirus-6, -7, and -8: Clinical implications for the immunocompromised host.
7. Tokyo Jikei University School of Medicine, Tokyo, Japan, February 27, 1997. Human herpesvirus-6, -7, and -8: Clinical implications for the immunocompromised host.
8. Nagoya University School of Medicine, Nagoya, Japan, February 28, 1997. Human herpesvirus-6, -7, and -8: Clinical implications for the immunocompromised host.
9. Osaka University School of Medicine, Osaka, Japan, March 3, 1997. Human herpesvirus-6, -7, and -8: Clinical implications for the immunocompromised host.
10. National Cancer Institute, Frederick, Maryland, May 5, 1997. Neonatal herpes simplex virus disease: Past achievements and future clinical needs.
11. Update '98: Clinical Management of Viral Infections, Whistler, British Columbia, Canada, February 10, 1998. Congenital viral infections in pregnancy.
12. Update '98: Clinical Management of Viral Infections, Whistler, British Columbia, Canada, February 10, 1998. VZV: Chickenpox: Vaccines/Treatments – New Drugs?
13. Mercer University School of Medicine Pediatric Grand Rounds, Macon, Georgia, October 13, 1998. Respiratory syncytial virus: natural history, management, and prevention.



14. University of Tennessee at Chattanooga Pediatric Grand Rounds, Chattanooga, Tennessee, October 14, 1998. Respiratory syncytial virus: natural history, management, and prevention.
15. Live televised satellite conference broadcast to 32 states plus the District of Columbia, February 10, 1999. Rotavirus and pneumococcal update. Sponsored by The Alabama Department of Public Health.
16. International Herpes Management Forum (IHMF) Vertical Transmission and Diagnostics Workshop, Nice, France, June 24, 1999. CMV infection in the neonate.
17. Costa Rican Association of Neonatology, IV Update Course in Neonatology, San Jose, Costa Rica, August 31, 1999. Herpes simplex virus infection in perinatology.
18. Costa Rican Association of Neonatology, IV Update Course in Neonatology, San Jose, Costa Rica, August 31, 1999. Respiratory syncytial virus infection.
19. Costa Rican Association of Neonatology, IV Update Course in Neonatology, San Jose, Costa Rica, September 1, 1999. Cytomegalovirus infection in perinatology.
20. American Academy of Pediatrics – Pediatric UPDATE Program (CME series produced on audiotape and in print), taped in Washington D.C., October 11, 1999. Perinatal infections. The two other panelists were Carol Baker, M.D., and Pablo Sánchez, M.D.
21. American Academy of Pediatrics 1999 Annual Meeting, Washington D.C., October 9-13, 1999. Interactive Case-Based Seminar (with Pablo Sánchez, M.D.): Perinatal infections: case presentations on diagnosis and treatment.
22. 2<sup>nd</sup> World Congress of Pediatric Infectious Diseases, Manila, Philippines, November 3, 1999. Neonatal herpes simplex virus infections: past achievements and future therapeutic options.
23. 2<sup>nd</sup> World Congress of Pediatric Infectious Diseases, Manila, Philippines, November 5, 1999. Management and treatment of congenital cytomegalovirus infection.
24. University of Connecticut Children’s Medical Center Pediatric Grand Rounds, Hartford, Connecticut, January 11, 2000. Neonatal herpes simplex virus infections: when to suspect and how to manage.
25. Meharry Medical School Pediatric Grand Rounds, Nashville, Tennessee, January 26, 2000. Pneumococcal disease: natural history, treatment, and prevention.
26. Update 2000: Clinical Management of Viral Infections, Whistler, British Columbia, Canada, February 6, 2000. Update on neonatal herpes simplex virus infections.

27. Children's Healthcare of Atlanta at Scottish Rite Hospital Pediatric Grand Rounds, Atlanta, Georgia, March 7, 2000. Pneumococcal disease in children.
28. University of Tennessee Pediatric Grand Rounds, Knoxville, Tennessee, April 13, 2000. Pneumococcal disease: natural history, treatment, and prevention.
29. 13<sup>th</sup> Infectious Diseases in Children Symposium, New York City, New York, November 18, 2000. Diagnosis and management of neonatal herpes simplex virus disease.
30. University of South Alabama Pediatric Grand Rounds, Mobile, Alabama, February 2, 2001. Neonatal herpes simplex virus infections: when to suspect and how to manage.
31. American Family Physicians 2001 Meeting, Tarrytown, New York, March 3, 2001. Current issues in genital herpes.
32. Society for Pediatric Research (SPR) and the Pediatric Infectious Diseases Society, Baltimore, Maryland, May 1, 2001. Advances in the antiviral therapy of congenital cytomegalovirus infection.
33. Mississippi Chapter of the American Academy of Pediatrics and The University of Mississippi Medical Center Spring Meeting, Jackson, Mississippi, May 17, 2001. Herpes simplex: the neonatal complexity.
34. Mississippi Chapter of the American Academy of Pediatrics and The University of Mississippi Medical Center Spring Meeting, Jackson, Mississippi, May 18, 2001. Congenital CMV: new treatments.
35. Common Problems in Pediatrics, Salt Lake City, Utah, June 12, 2001. Diagnosis of viral diseases.
36. Common Problems in Pediatrics, Salt Lake City, Utah, June 12, 2001. Viral therapy in pediatrics.
37. Regulatory Updates and Practical Strategies to Conduct Pediatric Clinical Trials (sponsored by PAREXEL International), Philadelphia, Pennsylvania, September 19, 2001. Managing pediatric subject recruitment from investigator site perspective.
38. American Academy of Pediatrics 2001 Annual Meeting, San Francisco, California, October 23, 2001. Plenary Session: New treatment of congenital CMV.
39. American Academy of Pediatrics 2001 Annual Meeting, San Francisco, California, October 23, 2001. Interactive Case-Based Seminar (with Keith Krasinski, M.D.): Diagnosis and treatment of childhood encephalitis and viral meningitis.
40. American Academy of Pediatrics 2001 Annual Meeting, San Francisco, California,

- October 24, 2001. Seminar (with Charles Prober, M.D.): New antiviral agents for the pediatrician.
41. Regulatory Updates and Practical Strategies to Conduct Pediatric Clinical Trials (sponsored by PAREXEL International), Philadelphia, Pennsylvania, December 6, 2001. Managing pediatric subject recruitment from investigator site perspective.
  42. Update 2002: Clinical Management of Viral Infections, Whistler, British Columbia, Canada, February 12, 2002. Pediatric uses of antiherpesviral medications: what's right?
  43. Update 2002: Clinical Management of Viral Infections, Whistler, British Columbia, Canada, February 12, 2002. Preventing neonatal herpes.
  44. National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group (CASG) Annual Meeting, Bethesda, Maryland, February 21, 2002. Clinical presentation as predictor of outcome in neonatal HSV disease: Combined analyses of 20 years of data.
  45. Regulatory Updates and Practical Strategies to Conduct Pediatric Clinical Trials (sponsored by PAREXEL International), Philadelphia, Pennsylvania, March 8, 2002. Managing pediatric subject recruitment from investigator site perspective.
  46. NIDCD/NIH Workshop "Congenital Cytomegalovirus Infection and Hearing Loss," Rockville, MD, March 19, 2002. Treatment of hearing loss in infants with symptomatic congenital CMV infection.
  47. Duke Clinical Research Institute Pediatric Research Summit, Washington D.C., April 11-13, 2002. Roundtable discussant.
  48. International Herpes Management Forum (IHMF) Herpesvirus Infections of the CNS Workshop, Denver, Colorado, April 21, 2002. Herpesviral meningitis and encephalitis in neonates.
  49. 18<sup>th</sup> International Union Against Sexually Transmitted Diseases (IUSTI) Europe Congress on Sexually Transmitted Diseases, Vienna, Austria, September 14, 2002. Vertical transmission of herpes simplex virus: acquisition and management during pregnancy.
  50. Regulatory Updates and Strategies for Recruitment, IRB Approvals, and Trial Design in the Conduct of Pediatric Clinical Trials (sponsored by PAREXEL International), Philadelphia, Pennsylvania, September 20, 2002. Educating the pharmaceutical industry on support networks for pediatric studies (with Charles Prober, M.D.).
  51. American Academy of Pediatrics 2002 Annual Meeting, Boston, Massachusetts, October 19-23, 2002. Seminar (with Bill Raszka, M.D.): New antibiotics, antivirals, and other

anti-infectives.

52. 15<sup>th</sup> Infectious Diseases in Children Symposium, New York City, New York, November 16, 2002. Diagnosis and treatment of neonatal herpes.
53. International Herpes Management Forum (IHMF) 10<sup>th</sup> Annual Meeting, Paris, France, March 1, 2003. Neonatal herpes (Keynote Speaker).
54. Sacred Heart Hospital Pediatric Grand Rounds, Pensacola, Florida, March 25, 2003. Respiratory syncytial virus.
55. Tufts University Baystate Health Systems Grand Rounds, Springfield, Massachusetts, May 29, 2003. Perinatal herpes simplex virus transmission.
56. International Cytomegalovirus Congress 2003, Styria, Austria, June 13, 2003. Therapy of congenital cytomegalovirus infection (Keynote Speaker).
57. 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois; September 14, 2003. Focus Session on Congenital and Perinatal Infections.
58. Swedish Herpes Management Forum Annual Meeting, Stockholm, Sweden, October 2-3, 2003. Advances in the treatment of neonatal herpes simplex infections.
59. 41<sup>st</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Diego, California, October 12, 2003. Panelist for the Pediatric Issues Interactive Session.
60. Annual Meeting of the American College of Clinical Pharmacy, Dallas, Texas, October 23, 2004. Treating community-acquired gram-positive infections in children: when and how should we use new and established agents?
61. 18<sup>th</sup> International Conference on Antiviral Research (ICAR), Barcelona, Spain, April 13, 2005. Intrauterine-acquired viral infections: the hopes and possibilities for antiviral interventions (Keynote Speaker).
62. National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Disease (DMID), Bethesda, Maryland, October 3, 2005. Antiviral treatment of congenital CMV infections: Investigations by the NIAID Collaborative Antiviral Study Group.
63. 43<sup>rd</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Francisco, California, October 7, 2005. Meet-the-Professor Session: Antivirals in Children (including neonatal HSV).
64. American Academy of Pediatrics 2005 Annual Meeting, Washington, D.C., October 9,

2005. Selected Short Subject: Approach to the child with suspected meningitis. (Given twice in separate sessions).
65. Children's Hospital and Research Center at Oakland 35<sup>th</sup> Annual Fall Conference, Monterrey, California, November 11, 2005. Virology in general practice.
  66. Children's Hospital and Research Center at Oakland 35<sup>th</sup> Annual Fall Conference, Monterrey, California, November 11, 2005. The many faces of HSV.
  67. Children's Hospital and Research Center at Oakland 35<sup>th</sup> Annual Fall Conference, Monterrey, California, November 12, 2005. Practical use of antiviral agents.
  68. Jornada de Neonatología Meeting, Seville, Spain, November 19, 2005. Neonatal herpes simplex virus infections.
  69. Jornada de Neonatología Meeting, Seville, Spain, November 19, 2005. Congenital cytomegalovirus infections.
  70. Cleveland Clinic Pediatric Grand Rounds, Cleveland, Ohio, January 10, 2006. Antiviral management of congenital cytomegalovirus infections.
  71. Society for Pediatric Research (SPR), San Francisco, California, May 2, 2006. Meet the Red Book Committee: Update on new vaccines.
  72. University of Texas Health Science Center at San Antonio Pediatrics for the Practitioner Annual Teaching Conference, San Antonio, Texas, June 9, 2006. Virology in general practice.
  73. University of Texas Health Science Center at San Antonio Pediatrics for the Practitioner Annual Teaching Conference, San Antonio, Texas, June 9, 2006. The many faces of HSV.
  74. University of Texas Health Science Center at San Antonio Pediatrics for the Practitioner Annual Teaching Conference, San Antonio, Texas, June 9, 2006. When do I treat a viral infection?
  75. University of Texas Health Science Center at San Antonio Pediatrics for the Practitioner Annual Teaching Conference, San Antonio, Texas, June 9, 2006. Red Book 2006: What's New?
  76. State University of New York Stony Brook Grand Rounds, Stony Brook, New York, August 30, 2006. Antiviral management of congenital cytomegalovirus infections.
  77. 2006 Connecticut Neonatologists Annual Meeting, New Haven, Connecticut, October 3, 2006. Congenital cytomegalovirus infection and disease.

78. 2006 Connecticut Neonatologists Annual Meeting, New Haven, Connecticut, October 3, 2006. Neonatal herpes simplex virus infection and disease.
79. International Herpes Management Forum (IHMF) 13<sup>th</sup> Annual Meeting, Prague, Czech Republic, October 29, 2006. Hot Topic: Paediatric HSV and CMV infection.
80. 19<sup>th</sup> Infectious Diseases in Children Symposium, New York City, New York, November 19, 2006. Varicella.
81. Schneider Children's Hospital / Albert Einstein College of Medicine Grand Rounds, Manhasset, New York, March 23, 2007. Antiviral management of congenital cytomegalovirus infections.
82. Society for Pediatric Research (SPR), Toronto, Ontario, Canada, May 5, 2007. New antivirals and strategies for their use.
83. California Chapter of the American Academy of Pediatrics Annual CME Meeting, Las Vegas, Nevada, May 17-20, 2007. Update on vaccines.
84. California Chapter of the American Academy of Pediatrics Annual CME Meeting, Las Vegas, Nevada, May 17-20, 2007. The many faces of herpesviruses.
85. California Chapter of the American Academy of Pediatrics Annual CME Meeting, Las Vegas, Nevada, May 17-20, 2007. Virology in general practice.
86. California Chapter of the American Academy of Pediatrics Annual CME Meeting, Las Vegas, Nevada, May 17-20, 2007. Workshop: When do I treat a viral infection?
87. University of South Carolina Pediatric Update, Hilton Head Island, South Carolina, July 16, 2007. Virology in general practice.
88. University of South Carolina Pediatric Update, Hilton Head Island, South Carolina, July 17, 2007. When do I treat a viral infection?
89. University of South Carolina Pediatric Update, Hilton Head Island, South Carolina, July 18, 2007. Bacterial causes of otitis, sinusitis, and pharyngitis.
90. University of South Carolina Pediatric Update, Hilton Head Island, South Carolina, July 19, 2007. The many faces of herpesviruses.
91. PREP:ID 2007 (AAP ID Board Review Course), Chicago, Illinois, July 25, 2007. CNS viral infections.
92. PREP:ID 2007 (AAP ID Board Review Course), Chicago, Illinois, July 25, 2007. Hot

Topics.

93. PREP:ID 2007 (AAP ID Board Review Course), Chicago, Illinois, July 25, 2007. Herpes simplex and varicella-zoster viruses.
94. PREP:ID 2007 (AAP ID Board Review Course), Chicago, Illinois, July 25, 2007. Case vignettes for HSV and VZV.
95. PREP:ID 2007 (AAP ID Board Review Course), Chicago, Illinois, July 25, 2007. Herpesviruses: CMV, EBV, HHV-6, HHV-7, and HHV-8.
96. PREP:ID 2007 (AAP ID Board Review Course), Chicago, Illinois, July 25, 2007. Case vignettes for CMV, EBV, HHV-6, HHV-7, and HHV-8.
97. 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois, September 20, 2007. Diagnosis of herpes simplex virus infection in the neonate.
98. 45<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Diego, California, October 4, 2007. Hot Topics in Pediatric Infectious Diseases.
99. American Academy of Pediatrics 2007 Annual Meeting, San Francisco, California, October 29, 2007. Selected Short Subject: Update on congenital CMV: diagnosis, treatment, and prevention.
100. Seminar of the International Clinical Virology Society, Pucón, Chile, November 14, 2007. Use of ganciclovir in congenital infection of CMV.
101. Seminar of the International Clinical Virology Society, Pucón, Chile, November 14, 2007. Herpetic encephalitis management: diagnosis, therapy, and follow up.
102. University of Texas Southwestern Medical Center / Children's Medical Center of Dallas Grand Rounds, Dallas, Texas, January 9, 2008. Neonatal herpes simplex virus infection: presentation, treatment, and prevention.
103. 43<sup>rd</sup> Annual Miami Children's Hospital Postgraduate Course "Perspectives in Pediatrics," Miami, Florida, March 11, 2008. Special Session, Pinnacles of Infectious Diseases: Red Book 2008, Meet the Editors.
104. University of South Carolina Pediatric Infectious Diseases Update, Hilton Head Island, South Carolina, June 8-12, 2008. Virology in general practice.
105. University of South Carolina Pediatric Infectious Diseases Update, Hilton Head Island, South Carolina, June 8-12, 2008. When do I treat a viral infection?

106. University of South Carolina Pediatric Infectious Diseases Update, Hilton Head Island, South Carolina, June 8-12, 2008. Diagnosis, treatment, and prevention of influenza.
107. University of South Carolina Pediatric Infectious Diseases Update, Hilton Head Island, South Carolina, June 8-12, 2008. The many faces of herpesviruses.
108. Maimonides Infants and Children's Hospital of Brooklyn Grand Rounds, Brooklyn, New York, September 9, 2008. Neonatal herpes simplex virus infection: presentation, treatment, and prevention.
109. 21<sup>st</sup> Infectious Diseases in Children Symposium, New York City, New York, November 22, 2008. Neonatal herpes – diagnosis and management.
110. 44<sup>th</sup> Annual Miami Children's Hospital Postgraduate Course "Perspectives in Pediatrics," Miami, Florida, March 10, 2009. Special Session, Pinnacles of Infectious Diseases: Red Book 2009, Meet the Editors.
111. NIAID Influenza Antiviral Development Workshop, Bethesda, Maryland, March 26, 2009. Oseltamivir in Infants – Collaborative Antiviral Study Group (CASG).
112. 26<sup>th</sup> International Congress of Chemotherapy and Infection, Toronto, Canada, June 21, 2009. Neonatal herpes: The most treatable of the congenital and perinatal infections.
113. PREP:ID 2009 (AAP ID Board Review Course), Chicago, Illinois, July 14, 2009. Herpes Viruses I.
114. PREP:ID 2009 (AAP ID Board Review Course), Chicago, Illinois, July 14, 2009. Herpes Viruses II.
115. PREP:ID 2009 (AAP ID Board Review Course), Chicago, Illinois, July 14, 2009. CNS viral infections.
116. PREP:ID 2009 (AAP ID Board Review Course), Chicago, Illinois, July 14, 2009. Current trends (presented after each of the three sessions).
117. 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, September 14, 2009. Meet-the-Expert Session: What's New in Perinatal Infections and Infections in Pregnant Women.
118. American Academy of Pediatrics 2009 Annual Meeting, Washington D.C., October 19, 2009. Meet-the-Expert Session: Use of antivirals in general pediatrics.
119. American Academy of Pediatrics 2009 Annual Meeting, Washington D.C., October 19, 2009. Meet the Red Book.



120. 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 31, 2009. What's new in the 2009 Red Book?
121. European Society of Pediatric Infectious Diseases (ESPID) 2<sup>nd</sup> Advances in Pediatric Infectious Diseases meeting, Milan, Italy, November 4, 2009. Update on congenital CMV disease: Prevention and therapy.
122. Focus Diagnostics Microbiology Webnar Series, web-based international CME presentation, May 6, 2010. Herpes across the ages.
123. 10<sup>th</sup> Annual Neonatal Pharmacology Conference, Orlando, Florida, May 12, 2010. HSV and CMV.
124. 10<sup>th</sup> Annual Neonatal Pharmacology Conference, Orlando, Florida, May 12, 2010. H1N1 and oseltamivir.
125. American Academy of Pediatrics "Pediatrics in the Islands – Clinical Pearls 2010" meeting, Maui, Hawaii, July 4, 2010. Influenza treatment in children in the pandemic era.
126. American Academy of Pediatrics "Pediatrics in the Islands – Clinical Pearls 2010" meeting, Maui, Hawaii, July 4, 2010. When and how to use antiviral drugs in pediatric practice
127. American Academy of Pediatrics "Pediatrics in the Islands – Clinical Pearls 2010" meeting, Maui, Hawaii, July 4, 6, and 7, 2010. Neonatal herpes.
128. American Academy of Pediatrics "Pediatrics in the Islands – Clinical Pearls 2010" meeting, Maui, Hawaii, July 6, 2010. Red Book update.
129. American Academy of Pediatrics "Pediatrics in the Islands – Clinical Pearls 2010" meeting, Maui, Hawaii, July 7, 2010. Virology in general practice: beyond "it's just a virus."
130. American Academy of Pediatrics "Pediatrics in the Islands – Clinical Pearls 2010" meeting, Maui, Hawaii, July 8, 2010. Vaccine save lives, so why the pushback and what to do about it?
131. American Academy of Pediatrics 2010 Annual Meeting, San Francisco, California, October 3, 2010. Herpes simplex virus: the neonate and beyond. (Given twice in separate sessions).
132. 48<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, October 21, 2010, and October 23, 2010. Meet the Red Book.

133. Bradford Visiting Professor, Children's Mercy Hospital 43<sup>rd</sup> Clinical Advances in Pediatrics Symposium, Kansas City, Missouri, November 18, 2010. Neonatal herpes simplex virus infection: presentation, treatment, and prevention.
134. Bradford Visiting Professor, Children's Mercy Hospital 43<sup>rd</sup> Clinical Advances in Pediatrics Symposium, Kansas City, Missouri, November 18, 2010. Vaccine save lives, so why the pushback and what to do about it?
135. Bradford Visiting Professor, Children's Mercy Hospital 43<sup>rd</sup> Clinical Advances in Pediatrics Symposium, Kansas City, Missouri, November 18, 2010. Modification of RSV prophylaxis recommendations in the 2009 Red Book – why was it done, and what does it mean for you?
136. Jerry Elliott Memorial Lecturer, Southeastern Association of Neonatologists 25<sup>th</sup> Annual Conference, Marco Island, Florida, May 12, 2011. Universal screening and treatment of congenital cytomegalovirus disease: where are we now and how do we move forward?
137. Southeastern Association of Neonatologists 25<sup>th</sup> Annual Conference, Marco Island, Florida, May 13, 2011. Neonatal herpes: the most treatable of the congenital and perinatal infections.
138. Southeastern Association of Neonatologists 25<sup>th</sup> Annual Conference, Marco Island, Florida, May 14, 2011. Antiviral therapies for influenza in premature and term neonates and young infants.
139. International Meeting on Neonatal Infectious Diseases, Pavia, Italy, May 20, 2011. Herpes simplex virus infection: Management of the fetus and of the neonate.
140. European Society of Pediatric Infectious Diseases (ESPID) 2011 World Forum, The Hague, The Netherlands, June 10, 2011. Universal Screening and Treatment of Congenital Cytomegalovirus Disease: Where Are We Now and How Do We Move Forward?
141. American Academy of Pediatrics Red Book Webcast Series, June 16, 2011. Red Book Update 2011.
142. PREP:ID 2011 (AAP ID Board Review Course), Chicago, Illinois, July 26, 2011. CNS viral infections.
143. PREP:ID 2011 (AAP ID Board Review Course), Chicago, Illinois, July 26, 2011. Case vignettes for CNS viral infections.
144. PREP:ID 2011 (AAP ID Board Review Course), Chicago, Illinois, July 26, 2011. Herpes Viruses I (HSV, VZV).

145. PREP:ID 2011 (AAP ID Board Review Course), Chicago, Illinois, July 26, 2011. Case vignettes for HSV and VZV.
146. PREP:ID 2011 (AAP ID Board Review Course), Chicago, Illinois, July 26, 2011. Herpes Viruses II (CMV, EBV, HHV-6, HHV-7, HHV-8).
147. PREP:ID 2011 (AAP ID Board Review Course), Chicago, Illinois, July 26, 2011. Case vignettes for CMV, EBV, HHV-6, HHV-7, and HHV-8.
148. New York Medical College / Maria Fareri Children's Hospital Grand Rounds, Valhalla, New York, September 7, 2011. Universal screening and treatment of congenital cytomegalovirus disease: where are we now and how do we move forward?
149. New York Medical College / Maria Fareri Children's Hospital Neonatology Roundtable, Valhalla, New York, September 7, 2011. Neonatal herpes simplex virus infection.
150. 51<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois; September 19, 2011. Interactive Symposium on Cytomegalovirus: Diagnosis and Prevention of Congenital Cytomegalovirus.
151. American Academy of Pediatrics 2011 Annual Meeting, Boston, Massachusetts, October 16, 2011. Herpes simplex virus: the neonate and beyond. (Given twice in separate sessions).
152. 49<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA) Pediatric Infectious Disease Fellows Day Pre-Meeting Workshop, Boston, Massachusetts, October 20, 2011. Pediatric Fellows Day: Seeking Leadership Positions in our Field/Finding a Mentor.
153. American Academy of Pediatrics Practical Pediatrics CME Course, Anaheim, California, December 9, 2011. Vaccines Save Lives, So Why The Pushback and What To Do About It?
154. American Academy of Pediatrics Practical Pediatrics CME Course, Anaheim, California, December 10, 2011. Virology in General Practice: Beyond "It's Just a Virus"
155. American Academy of Pediatrics Practical Pediatrics CME Course, Anaheim, California, December 10, 2011. CNS Viral Infections.
156. American Academy of Pediatrics Practical Pediatrics CME Course, Anaheim, California, December 9, 2011, and December 10, 2011 (Given twice in separate sessions). What to Expect in the 2012 Red Book.
157. 22<sup>nd</sup> Challenge in Virology, Saanen, Switzerland, January 12-15, 2012. Congenital and perinatal viral infections: the narrow window of risk and the lifelong consequences of

- infection (invited expert to discuss management of neonatal and perinatal herpesvirus infections).
158. NeoPREP (AAP Neonatology Board Review Course), New Orleans, Louisiana, January 26, 2012. Viral Infections in the Neonate.
  159. NeoPREP (AAP Neonatology Board Review Course), New Orleans, Louisiana, January 26, 2012. Perinatally Acquired Diseases.
  160. American Academy of Pediatrics Practical Pediatrics CME Course, Orlando, Florida, March 23, 2012. Vaccines Save Lives, So Why The Pushback and What To Do About It?
  161. American Academy of Pediatrics Practical Pediatrics CME Course, Orlando, Florida, March 24, 2012. CNS Viral Infections.
  162. American Academy of Pediatrics Practical Pediatrics CME Course, Orlando, Florida, March 25, 2012. Neonatal herpes simplex virus infection: presentation, treatment, and prevention.
  163. American Academy of Pediatrics Practical Pediatrics CME Course, Orlando, Florida, March 23, 2012, March 24, 2012, and March 25, 2012 (given three times in separate sessions). What to Expect in the 2012 Red Book.
  164. 2012 Hugh Carithers Visiting Professor in Pediatric Infectious Diseases, University of Florida, Jacksonville, Florida, April 11, 2012. Neonatal herpes simplex virus infection: presentation, treatment, and prevention.
  165. Uniformed Services University of the Health Sciences Grand Rounds, Bethesda, Maryland, April 12, 2012. Neonatal herpes simplex virus disease.
  166. Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Boston, Massachusetts, April 28, 2012. Advances in the prevention and treatment of cytomegalovirus infection in the newborn.
  167. Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Boston, Massachusetts, April 30, 2012. Update on antivirals in the NICU: Getting the dose RIGHT, everytime.
  168. Richard F Jacobs, M.D. Lectureship in Infectious Disease, Arkansas Children's Hospital / University of Arkansas for Medical Sciences, Little Rock, Arkansas, May 29, 2012. Collaborative advances in the care of neonates with viral infections.
  169. Washington University School of Medicine and St. Louis Children's Hospital Pediatric UPDATE Program (CME series produced on audiotape and in print), taped in Atlanta, Georgia, June 19, 2012. Prevention and control of influenza in children. The two other

- panelists were Mike Brady, M.D., and Hank Bernstein, D.O.
170. 52<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, September 11, 2012. Red Book 2012.
  171. 52<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, September 11, 2012. HSV central nervous system infection in neonates and children: Diagnostic and treatment monitoring.
  172. Anticito Onlus International Meeting on Prevention and Therapy of Congenital Cytomegalovirus Infection, Rome, Italy, September 29, 2012. Antiviral therapy for congenital cytomegalovirus disease.
  173. IDWeek / 50<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Diego, California, October 19, 2012. Treatment and management of congenital cytomegalovirus infections.
  174. American Academy of Pediatrics 2012 Annual Meeting, New Orleans, Louisiana, October 23, 2012. Plenary Session – Neonatal HSV: New Insights Including Post-Treatment Prophylaxis.
  175. 25<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 17, 2012. Neonatal viral infections.
  176. New York Presbyterian - Weill Cornell Medical College Grand Rounds, New York City, New York, February 12, 2013. Neonatal herpes simplex virus and congenital cytomegalovirus infections.
  177. Medscape Influenza Prevention Spotlight Roundtable, Chicago, Illinois, February 27, 2013. Protecting the vulnerable: Influenza prevention and treatment in children younger than 5 years. The two other panelists were Andy Pavia, M.D., and Tina Tan, M.D.
  178. Visiting Professor, University of Colorado School of Medicine and Children's Hospital Colorado, March 14, 2013. Advances in the diagnosis and management of congenital cytomegalovirus disease.
  179. University of Colorado School of Medicine and Children's Hospital Colorado Grand Rounds, Denver, Colorado, March 15, 2013. Neonatal herpes simplex virus infections: When to suspect, and how to diagnose and manage.
  180. Rady Children's Hospital San Diego and the California Chapter of the American Academy of Pediatrics, San Diego, California, March 22, 2013. When and how to use antiviral drugs in pediatric practice.
  181. Rady Children's Hospital San Diego and the California Chapter of the American

- Academy of Pediatrics, San Diego, California, March 22, 2013. Red Book Update: Beyond 2012.
182. Rady Children's Hospital San Diego and the California Chapter of the American Academy of Pediatrics, San Diego, California, March 23, 2013. Vaccine advocacy: How can we better promote the life and health of our patients?
  183. Rady Children's Hospital San Diego and the California Chapter of the American Academy of Pediatrics, San Diego, California, March 23, 2013. Pulling the trigger on empiric acyclovir: when, how, and for whom?
  184. Tufts Medical Center Neonatal Grand Rounds, Boston, Massachusetts, March 28, 2013. Advances in the prevention and treatment of cytomegalovirus infection in the newborn.
  185. Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Washington D.C., May 5, 2013. Pulling the trigger on empiric acyclovir: when, how, and for whom?
  186. Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Washington D.C., May 5, 2013. Surveillance of encephalitis and encephalopathy in North America.
  187. Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Washington D.C., May 6, 2013. The epidemiology of vaccine hesitancy.
  188. Society of Hospital Medicine Meeting, Washington D.C., May 18, 2013. Neonatal HSV: When to Consider It, How to Evaluate for It, and How to Treat It.
  189. University of South Carolina Pediatric Infectious Diseases Update, Hilton Head Island, South Carolina, June 11, 2013. Pulling the trigger on empiric acyclovir: when, how, and for whom?
  190. University of South Carolina Pediatric Infectious Diseases Update, Hilton Head Island, South Carolina, June 12, 2013. CNS Viral Infections.
  191. University of South Carolina Pediatric Infectious Diseases Update, Hilton Head Island, South Carolina, June 13, 2013. Advances in the prevention and treatment of cytomegalovirus infection in the newborn.
  192. PREP:ID 2013 (AAP ID Board Review Course), Chicago, Illinois, July 23, 2013. CNS viral infections.
  193. PREP:ID 2013 (AAP ID Board Review Course), Chicago, Illinois, July 23, 2013. Herpes Viruses I (HSV, VZV).

194. PREP:ID 2013 (AAP ID Board Review Course), Chicago, Illinois, July 23, 2013. Herpes Viruses II (CMV, EBV, HHV-6, HHV-7, HHV-8).
195. University of Calgary Neonatal Grand Rounds, Alberta, Canada, September 17, 2013. Prevention and management of neonatal herpes simplex virus disease.
196. University of Calgary Pediatric Grand Rounds, Alberta, Canada, September 18, 2013. Prevention and management of congenital cytomegalovirus infection in pregnancy and following delivery.
197. IDWeek 2013 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Francisco, California, October 3, 2013. Meet-the-Professor Session: Red Book Update.
198. American Academy of Pediatrics “Aloha Update: Pediatrics 2013” meeting, Kauai, Hawaii, October 14, 2013. Encephalitis: Current concepts.
199. American Academy of Pediatrics “Aloha Update: Pediatrics 2013” meeting, Kauai, Hawaii, October 15, 2013. Influenza treatment and prevention in children in the post-pandemic era.
200. American Academy of Pediatrics “Aloha Update: Pediatrics 2013” meeting, Kauai, Hawaii, October 16, 2013. Red Book update: Beyond 2012.
201. American Academy of Pediatrics “Aloha Update: Pediatrics 2013” meeting, Kauai, Hawaii, October 17, 2013. Neonatal HSV: When to consider it, how to evaluate for it, and how to treat it.
202. American Academy of Pediatrics “Aloha Update: Pediatrics 2013” meeting, Kauai, Hawaii, October 17, 2013. Advances in the prevention and treatment of cytomegalovirus infection in the newborn.
203. American Academy of Pediatrics “Aloha Update: Pediatrics 2013” meeting, Kauai, Hawaii, October 14, 15, and 17, 2013. Vaccine Advocacy: How can we better promote the life and health of our patients?
204. American Academy of Pediatrics 2013 Annual Meeting, Orlando, Florida, October 27, 2013. Herpes viruses other than HSV.
205. American Academy of Pediatrics 2013 Annual Meeting, Orlando, Florida, October 27, 2013. Protecting neonates from serious infections: HSV and pertussis. Seminar with Kathryn Edwards.
206. American Academy of Pediatrics 2013 Annual Meeting, Orlando, Florida, October 28,

2013. Meet the Red Book.
207. The Fetus & Newborn: Improving Outcomes in Perinatal and Neonatal Care Preconference, Washington D.C., November 6, 2013. Antiviral therapies in the NICU: Neonatal herpes, congenital CMV, and beyond.
  208. The Fetus & Newborn: Improving Outcomes in Perinatal and Neonatal Care Conference, Washington D.C., November 7, 2013. Vaccines to prevent disease immediately after birth and throughout childhood.
  209. Lowell Glasgow Lecture at University of Utah Pediatric Grand Rounds, Salt Lake City, Utah, January 9, 2014. Updates in congenital CMV infection.
  210. Clinical and Translational Research Seminar at Nationwide Children's Hospital, Columbus, Ohio, March 18, 2014. Antiviral studies by the CASG: Past, Present, and Future.
  211. Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Vancouver, British Columbia, Canada, May 3, 2014. Congenital CMV infection: Longer therapy for all symptomatic babies?
  212. 32<sup>nd</sup> Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID) Walter Marget Educational Workshop, Dublin, Ireland, May 7, 2014. Managing congenital CMV.
  213. 32<sup>nd</sup> Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID), Dublin, Ireland, May 8, 2014. Meet the Professor (with Wendy Ferguson): Congenital CMV and toxoplasmosis.
  214. 32<sup>nd</sup> Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID), Dublin, Ireland, May 8, 2014. State of the art: Prevention and treatment of congenital CMV disease.
  215. Infection and Immunity in Children 11<sup>th</sup> Annual Course in Paediatric Infectious Diseases, Oxford, England, July 1, 2014. HSV in the neonatal period – when, why, and who to treat.
  216. Infection and Immunity in Children 11<sup>th</sup> Annual Course in Paediatric Infectious Diseases, Oxford, England, July 1, 2014. The evidence for treatment of influenza in children.
  217. Louisiana Chapter of the American Academy of Pediatrics Red Stick Pediatric Potpourri, Baton Rouge, Louisiana, August 22, 2014. Encephalitis: Current concepts.
  218. Louisiana Chapter of the American Academy of Pediatrics Red Stick Pediatric Potpourri, Baton Rouge, Louisiana, August 22, 2014. Neonatal HSV: When to consider it, how to



evaluate it, and how to treat it.

219. Dell Children's Medical Center Grand Rounds, Austin, Texas, September 19, 2014. Advances in the prevention and treatment of herpes simplex virus infections in the neonate.
220. Utah CMV Public Health and Policy Conference, Salt Lake City, Utah, September 26, 2014. Diagnosis and treatment of congenital cytomegalovirus disease (Plenary Speaker).
221. IDWeek 2014 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), Philadelphia, Pennsylvania, October 8, 2014. Pediatric Fellows Day: Seeking Leadership Positions in our Field/Finding a Mentor.
222. IDWeek 2014 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), Philadelphia, Pennsylvania, October 9, 2014. Meet-the-Professor Session: Red Book Update.
223. IDWeek 2014 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), Philadelphia, Pennsylvania, October 9, 2014. Treatment of neonatal and infant CMV infections – Who should be treated?
224. California Chapter of the American Academy of Pediatrics 31<sup>st</sup> Annual Current Advances in Pediatrics, Newport Beach, California, October 24, 2014. Red Book Update: What To Expect in 2015.
225. California Chapter of the American Academy of Pediatrics 31<sup>st</sup> Annual Current Advances in Pediatrics, Newport Beach, California, October 24, 2014. Neonatal HSV: The spectrum of disease.
226. California Chapter of the American Academy of Pediatrics 31<sup>st</sup> Annual Current Advances in Pediatrics, Newport Beach, California, October 25, 2014. Ebola and chikungunya.
227. California Chapter of the American Academy of Pediatrics 31<sup>st</sup> Annual Current Advances in Pediatrics, Newport Beach, California, October 25, 2014. Influenza treatment and prevention.
228. California Chapter of the American Academy of Pediatrics 31<sup>st</sup> Annual Current Advances in Pediatrics, Newport Beach, California, October 26, 2014. Advances in the prevention and treatment of cytomegalovirus infection in the newborn.
229. 27<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 23, 2014. Red Book Update: What To Expect in 2015.

230. Doctors Hospital at Renaissance 2<sup>nd</sup> Annual Pediatric Conference, McAllen, Texas, January 17, 2015. Update on Pediatric Immunizations.
231. 24<sup>th</sup> International Paediatric Infectious Diseases Conference, Banff, Alberta, Canada, February 12, 2015. Red Book Update: What to Expect in 2015.
232. 24<sup>th</sup> International Paediatric Infectious Diseases Conference, Banff, Alberta, Canada, February 13, 2015. Emerging and Reemerging Infections.
233. St. Jude/PIDS 14<sup>th</sup> Annual Pediatric Infectious Diseases Research Conference, Memphis, Tennessee, February 21, 2015. Leading a research team.
234. St. Jude/PIDS 14<sup>th</sup> Annual Pediatric Infectious Diseases Research Conference, Memphis, Tennessee, February 21, 2015. Career mapping: Where are you, and where are you going?
235. Saint Barnabas Medical Center Grand Rounds, Livingston, New Jersey, March 24, 2015. Neonatal herpes simplex virus disease.
236. Newark Beth Israel Medical Center Children's Hospital Grand Rounds, Newark, New Jersey, March 25, 2015. Congenital cytomegalovirus infection.
237. 5<sup>th</sup> International Congenital CMV Conference & 15<sup>th</sup> International CMV/Betaherpesvirus Workshop, Brisbane, Australia, April 20, 2015. Therapy of neonates for congenital CMV.
238. 5<sup>th</sup> International Congenital CMV Conference & 15<sup>th</sup> International CMV/Betaherpesvirus Workshop, Brisbane, Australia, April 20, 2015. Expert Panel: Neonatal screening – Outcomes of US and Consensus Recommendations Meeting.
239. PREP:ID 2015 (AAP ID Board Review Course), Chicago, Illinois, August 22, 2015. CNS viral infections.
240. PREP:ID 2015 (AAP ID Board Review Course), Chicago, Illinois, August 22, 2015. Herpes Viruses I (HSV, VZV).
241. PREP:ID 2015 (AAP ID Board Review Course), Chicago, Illinois, August 22, 2015. Herpes Viruses II (CMV, EBV, HHV-6, HHV-7, HHV-8).
242. PREP:ID 2015 (AAP ID Board Review Course), Chicago, Illinois, August 22, 2015. Red Book Update (with Hank Bernstein).
243. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / International Congress on Chemotherapy (ICC), San Diego, California, September 19,

2015. Meet-the-Expert: New therapies for CMV in the immunocompromised host.
244. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / International Congress on Chemotherapy (ICC), San Diego, California, September 21, 2015. Meet-the-Expert: Management of HSV infections in 2015.
245. Philip Porter Lecture at Harvard University and Mass General Hospital for Children Grand Rounds, Boston, Massachusetts, September 29, 2015. Advances in the treatment of congenital CMV infection – a rationale for universal testing of all newborns?
246. IDWeek 2015 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Diego, California, October 9, 2015. Meet-the-Professor Red Book Update.
247. American Academy of Pediatrics 2015 Annual Meeting, Washington, D.C., October 25, 2015. Update on CMV and HSV in the Neonate/Young Infant.
248. 9<sup>th</sup> World Congress of Pediatric Infectious Diseases, Rio de Janeiro, Brazil, November 19, 2015. Meet the Professor: CMV Treatment.
249. 9<sup>th</sup> World Congress of Pediatric Infectious Diseases, Rio de Janeiro, Brazil, November 19, 2015. Screening For and Treating Congenital CMV.
250. 9<sup>th</sup> World Congress of Pediatric Infectious Diseases, Rio de Janeiro, Brazil, November 19, 2015. Management of Neonatal HSV Infections in 2015.
251. 28<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 21, 2015. Red Book Update – What’s New in 2015?
252. 28<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 21, 2015. Head Lice Update: Costs and Effectiveness of Treatments.
253. University of North Carolina Floyd Denny Professor Lectureship and Grand Rounds, Chapel Hill, North Carolina, February 4, 2016. Neonatal HSV and congenital CMV: Advances in diagnosis and treatment.
254. University of North Carolina Noon Resident Conference, Chapel Hill, North Carolina, February 4, 2016. Red Book Update – What’s New in 2015?
255. Temple Street Children’s University Hospital Study Day, Dublin, Ireland, February 12, 2016. Keynote Speaker: Treatment of congenital CMV.
256. *Eunice Kennedy Shriver* National Institute of Child Health and Human Development 2015-2016 Principles of Pediatric Clinical Pharmacology Lecture Series webinar, March

- 16, 2016: Clinical Pharmacology of Infectious Disease Agents in Children.
257. 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, The Netherlands, April 9, 2016. Neonatal herpes simplex virus: epidemiology and treatment.
  258. Australasian Society for Infectious Diseases (ASID) Annual Scientific Meeting, Launceston, Australia, April 21, 2016. Keynote Presentation: Advances in the treatment of congenital CMV infection – a rationale for universal testing of all newborns?
  259. Australasian Society for Infectious Diseases (ASID) Annual Scientific Meeting, Launceston, Australia, April 22, 2016. Congenital HSV.
  260. Hospital for Sick Children Grand Rounds, Toronto, Ontario, Canada, May 11, 2016. Advances in the prevention and treatment of cytomegalovirus infection in the newborn.
  261. Hospital for Sick Children Plenary, Toronto, Ontario, Canada, May 11, 2016. Red Book Update – The Biggest Challenges in Evidence Based Infectious Diseases Guidelines.
  262. International Meeting on Neonatal Infectious Diseases, Pavia, Italy, June 9, 2016. Infezioni da CMV e HSV: cosa c'è di nuovo? (Cytomegalovirus and herpes simplex virus infection: what's new?)
  263. CMV Public Health and Policy Conference, Austin, Texas, September 26-27, 2016. Is Universal Newborn CMV Screening Good Public Health Policy? (Plenary Speaker).
  264. The Fetus & Newborn: Improving Outcomes in Perinatal and Neonatal Care Conference, New Orleans, Louisiana, September 29, 2016. Neonatal HSV and congenital CMV: Advances in diagnosis and treatment.
  265. The Fetus & Newborn: Improving Outcomes in Perinatal and Neonatal Care Conference, New Orleans, Louisiana, September 30, 2016. Red Book Update – Developments Since the 2015 Edition.
  266. IDWeek 2016 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), New Orleans, Louisiana, October 28, 2016. Meet-the-Professor Red Book Update.
  267. 29<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 20, 2016. New COID Statements Since the 2015 Red Book.
  268. Herpes Virus Seminar, Clinica Alemana Universidad de Desarrollo, Santiago, Chile, December 1, 2016. Neonatal herpes simplex virus disease: when to suspect and how to manage.

269. Herpes Virus Seminar, Clinica Alemana Universidad de Desarrollo, Santiago, Chile, December 1, 2016. Advances in the prevention and treatment of cytomegalovirus infection in the newborn.
270. Herpes Virus Seminar, Clinica Alemana Universidad de Desarrollo, Santiago, Chile, December 2, 2016. Herpesvirus infections of the central nervous system beyond the neonatal period.
271. *Eunice Kennedy Shriver* National Institute of Child Health and Human Development 2016-2017 Principles of Pediatric Clinical Pharmacology Lecture Series webinar, February 8, 2017: Pharmacotherapy of Infectious Diseases – Viral Disorders.
272. XIX National Neonatology Congress, Mérida (Yucatan), Mexico, February 3, 2017. Neonatal HSV and congenital CMV: Advances in diagnosis and treatment.
273. XIX National Neonatology Congress, Mérida (Yucatan), Mexico, February 3, 2017. Red Book Update – Developments Since the 2015 Edition.
274. Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, San Francisco, California, May 7, 2017. Herpes simplex virus infection.
275. University of California San Francisco's 50<sup>th</sup> Annual Advances & Controversies in Clinical Pediatrics, San Francisco, California, June 9, 2017. CMV in Newborns: Advances in Prevention and Treatment.
276. University of California San Francisco's 50<sup>th</sup> Annual Advances & Controversies in Clinical Pediatrics, San Francisco, California, June 9, 2017. Neonatal HSV: When To Suspect and How To Manage
277. University of California San Francisco's 50<sup>th</sup> Annual Advances & Controversies in Clinical Pediatrics, San Francisco, California, June 10, 2017. Red Book Update: What Will Be New in 2018?
278. PREP:ID / Nelson's Antimicrobial Therapy 2017 (AAP ID Board Review Course), Dallas, Texas, July 29, 2017. CNS Infections.
279. PREP:ID / Nelson's Antimicrobial Therapy 2017 (AAP ID Board Review Course), Dallas, Texas, July 30, 2017. Antiviral Therapeutics.
280. PREP:ID / Nelson's Antimicrobial Therapy 2017 (AAP ID Board Review Course), Dallas, Texas, July 30, 2017. HSV.
281. Carolinas HealthCare Levine Children's Hospital Grand Rounds, Charlotte, North Carolina, September 13, 2017. Congenital CMV Infection: Advances in Detection and

Treatment.

282. Charlotte Pediatric Society meeting, Charlotte, North Carolina, September 13, 2017. Red Book Update: What to Expect in 2018.
283. Schneider Children's Medical Center International Congenital CMV Conference, Tel Aviv, Israel, September 27, 2017. Treatment of congenital cytomegalovirus infection: A state-of-the-science assessment of current opportunities and limitations.
284. Vanderbilt University's 37<sup>th</sup> Annual Advances and Controversies in Neonatal Medicine, Nashville, Tennessee, November 9, 2017. Neonatal herpes simplex virus disease: When to suspect and how to manage.
285. Vanderbilt University's 37<sup>th</sup> Annual Advances and Controversies in Neonatal Medicine, Nashville, Tennessee, November 10, 2017. Advances in the treatment of congenital cytomegalovirus infection – A rationale for universal testing of all newborns?
286. 30<sup>th</sup> Annual Infectious Diseases in Children Symposium, New York City, New York, November 19, 2017. Mononucleosis Update.
287. Chartrand Memorial Lectureship Grand Rounds, Creighton University, Omaha, Nebraska, December 1, 2017. Diagnostic and therapeutic advances in congenital and perinatal infections: Neonatal HSV and congenital CMV.
288. University of Tennessee at Chattanooga Pediatric Grand Rounds, Chattanooga, Tennessee, January 24, 2018. What Will Be New in the 2018 Red Book?
289. American Academy of Pediatrics “Pediatric Potpourri – State of the Art 2018” meeting, Maui, Hawaii, February 25, 2018. Group A Strep Update.
290. American Academy of Pediatrics “Pediatric Potpourri – State of the Art 2018” meeting, Maui, Hawaii, February 25, February 28, and March 1, 2018. What Will Be New in the 2018 Red Book?
291. American Academy of Pediatrics “Pediatric Potpourri – State of the Art 2018” meeting, Maui, Hawaii, February 26, 2018. Congenital Zika.
292. American Academy of Pediatrics “Pediatric Potpourri – State of the Art 2018” meeting, Maui, Hawaii, February 28, 2018. Congenital CMV.
293. American Academy of Pediatrics “Pediatric Potpourri – State of the Art 2018” meeting, Maui, Hawaii, March 1, 2018. EBV Update (Beyond Mononucleosis).
294. *Eunice Kennedy Shriver* National Institute of Child Health and Human Development 2017-2018 Principles of Pediatric Clinical Pharmacology Lecture Series webinar, April 4,

- 2018: Pharmacotherapy of Infectious Diseases – Viral Disorders.
295. University of Texas Southwestern Medical Center / Children’s Medical Center of Dallas Grand Rounds, Dallas, Texas, May 9, 2018. The Odyssey of Therapeutic Discovery: Antiviral Drug Development Programs.
  296. 31<sup>st</sup> International Conference on Antiviral Research, Porto, Portugal, June 14, 2018. Treatment of Congenital CMV Infection: New Populations, New Regimens, and New Drugs?
  297. 36<sup>th</sup> Annual Conference on Pediatric Infectious Diseases, Children’s Hospital Colorado, Vail, Colorado, July 30, 2018. Diagnosing and Managing Congenital CMV, Neonatal Herpes, and Congenital Zika.
  298. 36<sup>th</sup> Annual Conference on Pediatric Infectious Diseases, Children’s Hospital Colorado, Vail, Colorado, July 31, 2018. New Developments and Recommendations in the 2018 Red Book.
  299. National Institutes of Health NIAID/NICHD Workshop on Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment, September 4-6, 2018. Treatment of congenital CMV past, present, and future (including drug combinations) (on September 4, 2018).
  300. Italian Society of Neonatology Annual Meeting, Rome, Italy, September 27, 2018. Plenary Speaker: Neonatal Viral Infections.
  301. IDWeek 2018 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Francisco, California, October 7, 2018. Red Book Update.
  302. Congenital CMV From Pregnancy to Infancy, Florence, Italy, February 21, 2019. Treatment of Congenital CMV Infection: New Populations, New Regimens, and New Drugs?
  303. Congenital CMV From Pregnancy to Infancy, Florence, Italy, February 21, 2019. Deciding to Treat Symptomatic Congenital CMV: Extent of Involvement and Use of Biomarkers.
  304. *Eunice Kennedy Shriver* National Institute of Child Health and Human Development 2018-2019 Principles of Pediatric Clinical Pharmacology Lecture Series webinar, March 6, 2019: Pharmacotherapy of Viral Disorders in Children.

#### **INVITED ORAL LECTURES AT LOCAL AND REGIONAL MEETINGS**

1. University of Alabama at Birmingham Perinatal Grand Rounds, Birmingham, Alabama,

- November, 1995. Evaluation and management of congenital syphilis.
2. University of Alabama at Huntsville Pediatric Grand Rounds, Huntsville, Alabama, December, 1995. New issues in antiviral chemotherapy.
  3. Alabama Society of Health-System Pharmacists, Birmingham, Alabama, November 6, 1997. Human immunodeficiency virus infection in pediatrics.
  4. Alabama State Nurses Association – Nurse Practitioners Council, Gulf Shores, Alabama, April 25, 1998. Sexually transmitted diseases, 1998.
  5. Baptist Health System Neonatal Grand Rounds, Montgomery, Alabama, September 16, 1998. Antibiotic management in the neonatal intensive care unit setting.
  6. Samford University, Birmingham, Alabama, October 1, 1998. HIV infection and disease.
  7. University of Alabama at Birmingham Pediatric GI/Nutrition Update (CME), February 27, 1999. Hepatitis C virus infection: natural history and evolving therapeutic options.
  8. Samford University, Birmingham, Alabama, March 9, 1999. HIV infection and disease.
  9. Carraway Family Practice Residency Program Grand Rounds, Birmingham, Alabama, March 17, 1999. Neonatal herpes simplex virus disease: past achievements and future clinical needs.
  10. American Practitioners of Infection Control and Epidemiology, Alabama Chapter, Birmingham, Alabama, April 28, 1999. Overview of evaluation and prevention of selected infections in neonates and infants.
  11. Carraway Methodist Hospital Medical Grand Rounds, Birmingham, Alabama, May 18, 1999. Genital herpes and syphilis.
  12. Children’s Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, July 29, 1999. Hepatitis C virus infection: natural history and evolving therapeutic options.
  13. Children’s Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, October 14, 1999. Infantile histoplasmosis.
  14. Samford University, Birmingham, Alabama, October 28, 1999. HIV infection and disease.
  15. Carraway Methodist Hospital Medical Grand Rounds, Birmingham, Alabama, February 15, 2000. Sexually transmitted diseases.
  16. State of Alabama Department of Public Health State Immunization Staff Meeting,



- Birmingham, Alabama, February 18, 2000. Pneumococcal disease prevention.
17. Tennessee State Nursing Staff Meeting, Franklin, Tennessee, March 23, 2000. Pneumococcal disease prevention.
  18. Samford University, Birmingham, Alabama, April 6, 2000. HIV infection and disease.
  19. Alabama Primary Healthcare Association Policy and Issue Conference, Montgomery, Alabama, April 12, 2000. Hepatitis B virus vaccination in infants and adolescents.
  20. Alabama Medical Directors Association Annual Meeting, Sandestin, Florida, July 22, 2000. Prevention and management of influenza and pneumococcal disease.
  21. Alabama Primary Healthcare Association Annual Meeting, Orange Beach, Alabama, September 7, 2000. Hepatitis B virus infection and prevention.
  22. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, September 14, 2000. Influenza update: prevention and new therapeutic options.
  23. Samford University, Birmingham, Alabama, November 2, 2000. HIV infection and disease.
  24. Mobile Pediatric Society Meeting, Mobile, Alabama, February 1, 2001. Hepatitis: the alphabet soup of infectious diseases.
  25. Baptist Health System Pediatric Grand Rounds, Montgomery, Alabama, April 17, 2001. Neonatal herpes.
  26. San Antonio Dermatological Society Meeting, San Antonio, Texas, April 19, 2001. Varicella zoster virus: spectrum of disease.
  27. Alabama Focus On Children Conference, Birmingham, Alabama, October 25, 2001. Maintaining public confidence in vaccines.
  28. STD Update 2001, The University of Alabama at Birmingham, Birmingham, Alabama, November 8, 2001. Genital herpes.
  29. University of Alabama at Huntsville Pediatric Grand Rounds, Huntsville, Alabama, January 18, 2002. Neonatal herpes simplex virus disease.
  30. University of Alabama at Birmingham Perinatal Grand Rounds, Birmingham, Alabama, February 26, 2002. Viral infections during pregnancy and in the newborn.
  31. Samford University, Birmingham, Alabama, April 9, 2002. HIV infection and disease.

32. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 19, 2002. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
33. Samford University, Birmingham, Alabama, October 29, 2002. HIV infection and disease.
34. Alabama Chapter of the American Academy of Family Physicians Annual Meeting, Birmingham, Alabama, December 6, 2002. Bioterrorism update.
35. Alabama Chapter of the American Academy of Pediatrics Annual Meeting, Birmingham, Alabama, January 25, 2003. Bioterrorism update.
36. Alabama Chapter of the American Academy of Pediatrics Annual Meeting, Birmingham, Alabama, January 25, 2003. Redbook update.
37. University of Alabama at Birmingham K30 Clinical Research Training Program, Birmingham, Alabama, February 12, 2003. Phase I, II, and III clinical trials.
38. University of Alabama at Birmingham K30 Clinical Research Training Program, Birmingham, Alabama, March 4, 2003. Managing your academic career.
39. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 6, 2003. Sexually transmitted diseases in pregnancy and associated neonatal complications.
40. University of Alabama at Birmingham Scooter Haywood Conference on Neonatal Care, Birmingham, Alabama, March 8, 2003. Antibiotic resistance and overuse.
41. University of Alabama at Birmingham Nurse Practitioners Pharmacology Workshop, Birmingham, Alabama, April 4, 2003. Choosing appropriate antibiotics.
42. Samford University, Birmingham, Alabama, April 8, 2003. HIV infection and disease.
43. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 18, 2003. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
44. Samford University, Birmingham, Alabama, October 28, 2003. HIV infection and disease.
45. University of Alabama at Birmingham Infectious Diseases Grand Rounds, Birmingham, Alabama, November 6, 2003. Neonatal herpes.
46. University of Alabama at Birmingham K30 Clinical Research Training Program,

- Birmingham, Alabama, January 14, 2004. Phase I, II, and III clinical trials.
47. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 4, 2004. Sexually transmitted diseases in pregnancy and associated neonatal complications.
  48. Samford University, Birmingham, Alabama, March 16, 2004. HIV infection and disease.
  49. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 16, 2004. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
  50. Samford University, Birmingham, Alabama, October 28, 2004. HIV infection and disease.
  51. University of Alabama at Birmingham Physical Medicine and Rehabilitation Grand Rounds, Birmingham, Alabama, February 11, 2005. The education of residents in clinical research.
  52. University of Alabama at Birmingham Acute Care Nurse Practitioner Program, Birmingham, Alabama, March 8, 2005. Common pediatric infectious diseases and their management.
  53. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 28, 2005. Sexually transmitted diseases in pregnancy and associated neonatal complications.
  54. Samford University, Birmingham, Alabama, March 30, 2005. HIV infection and disease.
  55. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, April 21, 2005. Blastomycosis in a child with paravertebral masses.
  56. Carraway Methodist Hospital Research Conference, Birmingham, Alabama, August 24, 2005. The role of clinical research in medicine.
  57. Pediatric Grand Rounds, Anniston, Alabama, August 25, 2005. Approach to the child with suspected meningitis.
  58. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 15, 2005. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
  59. Samford University, Birmingham, Alabama, October 12, 2005. HIV infection and disease.

60. University of Alabama at Birmingham Acute Care Nurse Practitioner Program, Birmingham, Alabama, January 24, 2006. Common pediatric infectious diseases and their management.
61. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 27, 2006. Sexually transmitted diseases in pregnancy and associated neonatal complications.
62. Samford University, Birmingham, Alabama, March 27, 2006. HIV infection and disease.
63. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, April 20, 2006. Disseminated neonatal herpes simplex virus disease in a baby with fulminant liver failure and coagulopathy.
64. Carraway Methodist Hospital Research Conference, Birmingham, Alabama, April 26, 2006. Clinical research protocol development.
65. University of Alabama at Birmingham Practical Day of Pediatrics, Birmingham, Alabama, May 12, 2006. Recent developments in vaccines.
66. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 21, 2006. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
67. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, October 12, 2006. Myocarditis in children.
68. Samford University, Birmingham, Alabama, October 18, 2006. HIV infection and disease.
69. Carraway Methodist Hospital Research Conference, Birmingham, Alabama, March 28, 2007. Presenting at scientific meetings.
70. Samford University, Birmingham, Alabama, March 28, 2007. HIV infection and disease.
71. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, April 5, 2007. Sexually transmitted diseases in pregnancy and associated neonatal complications.
72. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 21, 2007. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
73. University of Alabama at Birmingham K30 Clinical Research Training Program, Birmingham, Alabama, June 20, 2007. Investigator-initiated pilot clinical research: role

of the GCRC.

74. Samford University, Birmingham, Alabama, October 22, 2007. HIV infection and disease.
75. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 24, 2008. Sexually transmitted diseases in pregnancy and associated neonatal complications.
76. Samford University, Birmingham, Alabama, March 26, 2008. HIV infection and disease.
77. University of Alabama at Birmingham K30 Clinical Research Training Program, Birmingham, Alabama, June 18, 2008. Investigator-initiated pilot clinical research: role of the GCRC.
78. University of Alabama at Birmingham Annual Perinatal Conference, Birmingham, Alabama, July 29, 2008. Vaccination.
79. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 18, 2008. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
80. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, October 2, 2008. Neonatal herpes: when should you suspect it and how should you treat it?
81. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, February 5, 2009. Sexually transmitted diseases in pregnancy and associated neonatal complications.
82. CCTS Clinical and Translational Research Training Program, Birmingham, Alabama, March 4, 2009. Design of Clinical Trials Outcome Measurements, DSMB and Options.
83. 9<sup>th</sup> Annual Baby Steps to the Future: Care of the High Risk Newborn Conference, Sacred Heart Hospital, Pensacola, Florida, March 13, 2009. Identification and treatment of neonatal HSV infection.
84. 9<sup>th</sup> Annual Baby Steps to the Future: Care of the High Risk Newborn Conference, Sacred Heart Hospital, Pensacola, Florida, March 13, 2009. Presentation and emerging treatment options for congenital CMV disease.
85. Samford University, Birmingham, Alabama, March 23, 2009. HIV infection and disease.
86. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, August 27, 2009. Dispelling vaccine myths.

87. University of Alabama at Birmingham K30 Vocabulary of Clinical Research Course, Birmingham, Alabama, September 17, 2009. Interim analyses, early stopping rules, and DSMB evaluation of clinical trials.
88. Samford University, Birmingham, Alabama, October 28, 2009. HIV and other STI infections and disease.
89. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, February 15, 2010. Sexually transmitted diseases in pregnancy and associated neonatal complications.
90. CCTS Clinical and Translational Research Training Program, Birmingham, Alabama, March 3, 2010. Design of Clinical Trials Outcome Measurements, DSMB and Options.
91. Samford University, Birmingham, Alabama, March 24, 2010. HIV and other STI infections and disease.
92. University of Alabama at Birmingham Perinatal Grand Rounds, Birmingham, Alabama, March 31, 2010. Respiratory syncytial virus – new AAP recommendations for passive immunoprophylaxis.
93. State of Alabama Department of Public Health, DeKalb County Health Department Annual Public Health Camping Association Meeting, Fort Payne, Alabama, May 21, 2010. Pandemic influenza update.
94. Alabama Chapter of the American Academy of Pediatrics webinar, Alabama, July 15, 2010. Important Update on Mandatory School Immunization Requirements
95. University of Alabama at Birmingham Annual Perinatal Conference, Birmingham, Alabama, July 23, 2010. Respiratory syncytial virus.
96. Alabama Chapter of the American Academy of Pediatrics Immunization Congress, Birmingham, Alabama, September 24, 2010. Zeroing in on the challenge of vaccine refusal: What to do? (Keynote Speaker)
97. Samford Pharmacy School, Birmingham, Alabama, October 29, 2010. Dispelling vaccine myths.
98. Samford University, Birmingham, Alabama, November 29, 2010. HIV and other STI infections and disease.
99. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, February 16, 2011. Sexually transmitted diseases in pregnancy and associated neonatal complications.

100. CCTS Clinical and Translational Research Training Program, Birmingham, Alabama, March 16, 2011. Design of Clinical Trials Outcome Measurements, DSMB and Options.
101. Samford University, Birmingham, Alabama, April 20, 2011. HIV and other STI infections and disease.
102. Children's Hospital School Nurse Webinar, Birmingham, Alabama, May 9, 2011. Infections in school children: lice and scabies.
103. Samford Pharmacy School, Birmingham, Alabama, September 23, 2011. Dispelling vaccine myths.
104. Samford University, Birmingham, Alabama, November 16, 2011. HIV and other STI infections and disease.
105. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, February 9, 2012. Vaccine advocacy: How can we better promote the life and health of our patients?
106. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, February 14, 2012. Sexually transmitted diseases in pregnancy and associated neonatal complications.
107. CCTS Clinical and Translational Research Training Program, Birmingham, Alabama, February 15, 2012. Design of Clinical Trials Outcome Measurements, DSMB and Options.
108. University of Alabama at Birmingham Autism Masters Program, Birmingham, Alabama, March 17, 2012. Vaccines: Misinformation versus Fact.
109. Samford University, Birmingham, Alabama, April 25, 2012. HIV and other STI infections and disease.
110. Children's Hospital School Nurse Webinar, Birmingham, Alabama, September 5, 2012. 2012-2013 influenza recommendations.
111. Samford University, Birmingham, Alabama, December 3, 2012. HIV and other STI infections and disease.
112. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 5, 2013. Sexually transmitted diseases in pregnancy and associated neonatal complications.
113. Samford University, Birmingham, Alabama, December 2, 2013. HIV and other STI infections and disease.

114. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 4, 2014. Sexually transmitted diseases in pregnancy and associated neonatal complications.
115. Samford Pharmacy School Healthcare Ethics and Law Institute's Conference on Vaccines and Immunization Policies: Ethical and Legal Implications, Birmingham, Alabama, April 11, 2014. Impact of conscientious objection to vaccination of pediatric patients – parental rights versus societal obligations.
116. Samford University, Birmingham, Alabama, April 28, 2014. HIV and other STI infections and disease.
117. Samford University, Birmingham, Alabama, December 1, 2014. HIV and other STI infections and disease.
118. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 3, 2015. Sexually transmitted diseases in pregnancy and associated neonatal complications.
119. Samford University, Birmingham, Alabama, May 6, 2015. HIV and other STI infections and disease.
120. Children's of Alabama Nursing Education Seminar on Ethical Practice/ Quality Care, Birmingham, Alabama, May 15, 2015. Vaccines and public health – parental rights versus societal obligations.
121. Live televised satellite conference broadcast, May 19, 2015. Vaccines: they've got to be used to work – lessons from the 2015 measles outbreak. Sponsored by The Alabama Department of Public Health.
122. University of Alabama at Birmingham Center for Clinical and Translational Science's Comprehensive Research Education Seminar, Birmingham, Alabama, August 20, 2015. Building networks for research success.
123. University of Alabama at Birmingham Huntsville Pediatric Grand Rounds, Huntsville, Alabama, December 1, 2015. Neonatal HSV and congenital CMV.
124. University of Alabama at Birmingham Investigator Training Program, Birmingham, Alabama, January 21, 2016. PI oversight/overview during the study.
125. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, March 3, 2016. Sexually transmitted diseases in pregnancy and associated neonatal complications.
126. Samford Pharmacy School Healthcare Ethics and Law Institute's Conference on the



- Ethics and Policy of Drug Pricing in the U.S., Birmingham, Alabama, April 15, 2016. Patients in need of treatment: where policy and price meet either opportunity or impediment.
127. Children's of Alabama and Alabama Board of Nursing 2016 Statewide School Nurses Workshop, Birmingham, Alabama, June 15, 2016. Immunizations – the gift of life.
  128. Georgia AAP (American Academy of Pediatrics) State Chapter Fall Meeting, Atlanta, Georgia, September 23, 2016. Management of Neonatal HSV Infections in 2016.
  129. Georgia AAP (American Academy of Pediatrics) State Chapter Fall Meeting, Atlanta, Georgia, September 23, 2016. Red Book Update – Developments Since the 2015 Edition.
  130. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, October 6, 2016. Neonatal herpes simplex virus infections: Current knowledge, future opportunities.
  131. University of Alabama at Birmingham Center for Clinical and Translational Science Research Seminar, Birmingham, Alabama, November 17, 2016. Teamwork in clinical research (with Bari Cotton, RN).
  132. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, February 21, 2017. Sexually transmitted diseases in pregnancy and associated neonatal complications.
  133. University of Alabama at Birmingham Pediatric Cancer and Blood Disorders Symposium, Birmingham, Alabama, October 20, 2017. Viral infections in immune compromised host.
  134. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, February 20, 2018. Sexually transmitted diseases in pregnancy and associated neonatal complications.
  135. Children's Hospital Pediatric Medical Grand Rounds, Birmingham, Alabama, April 5, 2018. What Will Be New in the 2018 Red Book?
  136. Live televised satellite conference broadcast on Increasing HPV Vaccination Rates in Alabama, April 6, 2018. Human Papillomavirus Vaccine: AAP's Recommendations. Sponsored by The Alabama Department of Public Health.
  137. University of Alabama at Birmingham Medical School 2<sup>nd</sup> year medical student lecture, Birmingham, Alabama, January 7, 2019. Sexually transmitted diseases in pregnancy and associated neonatal complications.

## **PUBLICATIONS – ORIGINAL ARTICLES**

1. **Kimberlin DW**, Willis SA, McCracken GH, Jr., Nisen PD: Protein synthesis-dependent induction of interleukin-1 $\beta$  by lipopolysaccharide is inhibited by dexamethasone via mRNA destabilization in human astroglial cells. *J. Clin. Immunol.* 1995;15:199-204.
2. **Kimberlin DW**, Velasco S, Paris MM, Hickey SM, McCracken GH, Jr., Nisen PD: Modulation of expression of genes involved in the inflammatory response by lipopolysaccharide and temperature in cultured human astroglial cells. *Immunol. Invest.* 1995;24:775-785.
3. **Kimberlin D**, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong S-J, Lakeman A, Whitley R, and the NIAID Collaborative Antiviral Study Group: Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes, and mouth: results of a Phase I/II trial. *Pediatr. Infect. Dis. J.* 1996;15:247-254.[PubMed: 8852914].\*
4. **Kimberlin DW**, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. *J. Infect. Dis.* 1996;174:1162-1167. PubMed PMID: 8940204\*
5. **Kimberlin DW**, Lin C-Y, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, Murguía de Sierra T, Weller S, Soong S-J, Kiell J, Lakeman FD, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. *Pediatrics* 2001;108:230-238.[PubMed: 11483782].\*
6. **Kimberlin DW**, Lin C-Y, Jacobs RF, Powell DA, Frenkel L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, Murguía de Sierra T, Soong S-J, Kiell J, Lakeman FD, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: The natural history of neonatal herpes simplex virus infections in the acyclovir era. *Pediatrics* 2001;108:223-229.[PubMed: 11483781].\*
7. King JR, Acosta EP, Chadwick E, Yogev R, Crain M, Pass R, **Kimberlin DW**, Sturdevant MS, Aldrovandi GM: Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients. *Pediatr. Infect. Dis. J.* 2003;22:239-244.
8. Abzug MJ, Cloud G, Bradley J, Sánchez PJ, Romero J, Powell D, Lepow M, Mani C, Caparelli EV, Blount S, Lakeman F, Whitley RJ, and **Kimberlin DW**, on behalf of the Collaborative Antiviral Study Group: Double-blind, placebo-controlled trial of pleconaril

- in infants with enterovirus meningitis. *Pediatr. Infect. Dis. J.* 2003;22:335-40. PubMed PMID: 12690273\*
9. **Kimberlin DW**, Lin C-Y, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Kiell JM, Soong SJ, Whitley RJ, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Effect of ganciclovir on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. *J. Pediatr.* 2003;143:16-25. PubMed PMID: 12915819\*
  10. Bonner AB, Monroe KW, Talley LI, Klasner AE, **Kimberlin DW**: Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. *Pediatrics* 2003;112:363-367. PubMed PMID: 12897288
  11. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr., Connor EM, Sondheimer HM, for the Cardiac Synagis Study Group (**DWK is a member of Cardiac Synagis Study Group**): Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. *J. Pediatr.* 2003;143:532-540.
  12. DeVincenzo JP, Hall CB, **Kimberlin DW**, Sánchez PJ, Rodriguez WJ, Jantaush BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM: Surveillance of clinical respiratory syncytial virus (RSV) isolates for palivizumab resistant mutants. *J. Infect. Dis.* 2004;190:975-978. PubMed PMID: 15295704
  13. Bradford RD, Cloud G, Lakeman AD, Boppana S, **Kimberlin DW**, Jacobs R, Demmler G, Sánchez P, Britt W, Soong SJ, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. *J. Infect. Dis.* 2005;191:227-233. PubMed PMID: 15609232\*
  14. Acosta EP, Brundage RC, King JR, Griffin J, Cloud GA, Whitley RJ, **Kimberlin DW**, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid formulation of valganciclovir. *Clin. Pharmacol. Therapeut.* 2007;81:867-872. PubMed PMID: 17392728\*
  15. **Kimberlin DW**, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: A pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment

- of symptomatic congenital CMV disease. *J. Infect. Dis.* 2008;197:836-845. PubMed PMID:18279073\*
16. Benner K, Worthington M, **Kimberlin DW**, Hill K, Buckley K, Tofil N: Correlation of vancomycin dosing to serum concentrations in pediatric patients: A retrospective database review. *J. Pediatr. Pharmacol. Therapeut.* 2009;14(2):86-93.
  17. Oliver SE, Cloud GA, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RJ, Vaudry W, Pass RF, Soong SJ, Whitley RJ, **Kimberlin DW**. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. *J. Clin. Virol.* 2009;46(S):S22-S26. PubMed PMID:19766534; PubMed Central PMCID: PMC2805252\*
  18. Meissner HC, Bocchini JA, Brady MT, Hall CB, **Kimberlin DW**, Pickering LK: The role of immunoprophylaxis in the reduction of disease due to respiratory syncytial virus. *Pediatrics* December 2009;124(6):1676-1679. PubMed PMID:19948632
  19. **Kimberlin DW**, Jacobs RF, Weller S, van der Walt J-S, Heitman CK, Man CY, Bradley JS: Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month to 12 years of age. *Clin. Infect. Dis.* 2010;50:221-228. PubMed PMID:20014952
  20. **Kimberlin DW**, Shalabi M, Abzug MJ, Lang D, Jacobs RF, Storch G, Bradley JS, Wade K, Ramilo O, Romero JR, Shelton M, Leach C, Guzman-Cottrill J, Robinson J, Abughali N, Englund J, Griffin J, Jester P, Cloud GA, Whitley RJ, for the NIAID Collaborative Antiviral Study Group: Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age. *Pediatr. Infect. Dis. J.* 2010;29:195-198. PubMed PMID:19949363\*
  21. **Kimberlin DW**, Escude J, Gantner J, Ott J, Dronet M, Stewart T, Jester P, Redden DT, Chapman W, Hammond R: Targeted Antiviral Prophylaxis with Oseltamivir in a Summer Camp Setting. *Arch. Pediatr. Adolesc. Med.* 2010;164(4):323-327. PubMed PMID:20124132
  22. Acosta EP, Jester P, Gal P, Wimmer J, Wade J, Whitley RJ, **Kimberlin DW**, for the NIAID Collaborative Antiviral Study Group: Oseltamivir dosing for influenza infection in premature neonates. *J. Infect. Dis.* 2010;202(4):563-566. PubMed PMID: 20594104; PMCID: PMC2904429.\*
  23. **Kimberlin DW**, Whitley RJ, Wan W, Powell DA; Storch G, Ahmed A, Palmer A, Sánchez PJ, Jacobs RJ, Bradley JS, Robinson JL, Shelton M, Dennehy PH, Leach C, Rathore M, Abughali N, Wright P, Frenkel LM, Brady RC, Van Dyke R, Weiner LB, Guzman-Cottrill J, McCarthy CA, Griffin J, Jester P, Parker M, Lakeman FD, Kuo H, Lee CH, Cloud GA, for the NIAID Collaborative Antiviral Study Group: Oral acyclovir suppression and neurodevelopment after neonatal herpes. *N. Engl. J. Med.*

- 2011;365(14):1284-1292. PubMed PMID: 21991950; PMCID: PMC3250992. PMCID: PMC3250992.\*
24. Pinninti SG, Angara R, Feja KN, **Kimberlin DW**, Leach CT, Conrad DA, McCarthy CA, Tolan RW Jr: Neonatal herpes disease despite maternal antenatal antiviral suppressive therapy: A multicenter case series. *J. Pediatr.* 2012;161(1):134-138. PubMed PMID: 22336576.\*
  25. **Kimberlin DW**, Baley J, Committee on Infectious Diseases, Committee on Fetus and Newborn: Executive Summary: Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. *Pediatrics* 2013;131(2):383-386. PubMed PMID: 23378604.
  26. **Kimberlin DW**, Baley J, Committee on Infectious Diseases, Committee on Fetus and Newborn: Clinical Report: Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. *Pediatrics* 2013;131(2):e635-e646. PubMed PMID: 23359576.
  27. **Kimberlin DW**, Acosta EP, Prichard MN, Sánchez PJ, Ampofo K, Lang D, Ashouri N, Vanchiere JA, Abzug MJ, Abughali N, Caserta MT, Englund JA, Sood SK, Spigarelli MG, Bradley JS, Lew J, Michaels MG, Wan W, Cloud G, Jester P, Lakeman FD, Whitley RJ, for the NIAID Collaborative Antiviral Study Group: Oseltamivir pharmacokinetics, dosing, and resistance among children aged < 2 years with influenza. *J. Infect. Dis.* 2013;207:709-720. PubMed PMID: 23230059. PMCID: PMC3563309.\*
  28. Kamal MA, Acosta EP, **Kimberlin DW**, Gibiansky L, Jester P, Niranjana V, Rath B, Clinch B, Sánchez PJ, Ampofo K, Whitley R, Rayner CR: The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. *Clin. Pharmacol. Therapeut.* 2014;96(3):380-389. PubMed PMID: 24865390.\*
  29. **Kimberlin DW**, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels M, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han J-Y, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths P, Gutierrez K, Halasa N, Homans J, Shane A, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles G, Acosta EP, Whitley RJ, for the NIAID Collaborative Antiviral Study Group (CASG). Valganciclovir for symptomatic congenital cytomegalovirus disease. *N. Engl. J. Med.* 2015;372(10):933-943. PubMed PMID: 25738669. PMCID: PMC4401811.\*
  30. Abzug MJ, Michaels M, Wald E, Jacobs R, Romero J, Sanchez P, Wilson G, Krogstad P, Storch G, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood S, Cloud G, Jester P, Acosta EP, Whitley R, **Kimberlin D**, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates with Enterovirus

- Sepsis. *J. Pediatr. Infect. Dis. Soc.* 2016;5(1):53-62.\*
31. Hough-Telford C, **Kimberlin DW**, Aban I, Hitchcock WP, Almquist J, Kratz R, O'Connor KG. Vaccine Delays and Refusals and the Impact on Patient Dismissals: A Survey of Pediatricians. *Pediatrics.* 2016;138(3):e20162127. PubMed PMID: 27573091.
  32. Manthiram K, Li SC, Hausmann JS, Amarilyo G, Barron K, Kim H, Nativ S, Lionetti G, Zeft A, Goldsmith D, **Kimberlin D**, Edwards K, Dedeoglu F, Lapidus S, Childhood Arthritis and Rheumatology Research Alliance (CARRA) PFAPA Subcommittee. Physicians' Perspectives on the Diagnosis and Management of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. *Rheumatol Int.* 2017 Mar 7. doi: 10.1007/s00296-017-3688-3. [Epub ahead of print] PMID: 28271158
  33. Rawlinson W, Boppana S, Fowler KB, **Kimberlin DW**, Lazzarotto T, Alain S, Daly K, Doutré S, Gibson L, Giles ML, Greenlee J, Hamilton ST, Harrison GJ, Hui L, Jones CA, Palasanthiran P, Schleiss MR, Shand AW, van Zuylen WJ. Congenital Cytomegalovirus Infection in Pregnancy and the Neonate: Consensus Recommendations for Prevention, Diagnosis, and Therapy. *Lancet Infect. Dis.* 2017 Jun;17(6):e177-e188. doi: 10.1016/S1473-3099(17)30143-3. Epub 2017 Mar 11. PMID: 28291720
  34. Henderson B, **Kimberlin DW**, Forgie SE. Delayed recurrence of herpes simplex virus infection in the central nervous system after neonatal infection and completion of six months of suppressive therapy. *J. Pediatr. Infect. Dis. Soc.* 2017 Nov 24;6(4):e177-e179. PMID: 28379476
  35. Otto WR, Myers AL, LaRussa B, **Kimberlin DW**, Jackson MA. Clinical markers and outcomes of infants with herpes simplex virus DNA persistence in cerebrospinal fluid in disseminated and central nervous system infection. *J. Pediatr. Infect. Dis. Soc.* 2017 May 16. doi: 10.1093/jpids/pix033. [Epub ahead of print]
  36. Headrick A, Schmit EO, **Kimberlin DW**. Fulminant *Haemophilus influenzae* type a infection in a 4-year-old with previously undiagnosed asplenic heterotaxy. *Pediatr. Infect. Dis. J.* 2017 Aug 26. doi: 10.1097/INF.0000000000001758. [Epub ahead of print]
  37. Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, **Kimberlin DW**, Pahud B, DeBiasi RL, Yamamoto G, Roberts G, Hossain M, Shortino D, Yates PJ, Adams B, Peppercorn A. Intravenous Zanamivir in hospitalized patients with influenza. *Pediatrics* 2017 Nov;140(5). pii: e20162727. doi: 10.1542/peds.2016-2727.

## **PUBLICATIONS – ORIGINAL ARTICLES – Submitted**

1. Li XJ, Hui MK, Ison MG, Khanna N, Zhao RY, Li G, **Kimberlin DW**. An Assay for Rapid Determination of Influenza Types A or B Virus Susceptibility to Oseltamivir. *Antimicrob. Agents Chemother.* 2017.

## **PUBLICATIONS – ORIGINAL ARTICLES – In Preparation**

1. **Kimberlin DW**, Abdullatif H, Jacobs RF, Storch G, Robinson J, Ford-Jones L, McKercher S, Griffin J, Jester P, Cloud GA, Whitley RJ, for the NIAID Collaborative Antiviral Study Group: Pubertal and cancer follow-up of adolescents treated in early infancy with ganciclovir for congenital cytomegalovirus disease. 2017.\*
2. Wiltrakis SM, Cloud GA, Whitley RJ, Sánchez PJ, Ampofo K, Lang D, Ashouri N, Vanchiere JA, Abzug MJ, Abughali N, Caserta MT, Englund JA, Sood SK, Spigarelli MG, Bradley JS, Lew J, Michaels MG, Jester PM, **Kimberlin DW**, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Influenza Symptoms and Severity Predictors in Infants and Young Children. 2017.\*
3. Wang K, **Kimberlin DW**, Prichard MN, Whitley RJ, Acosta EP, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Drug-Disease Modeling of Oseltamivir and Oseltamivir Carboxylate in Infants with Influenza Virus Infection. 2017.\*
4. Oliver SE, Potter JL, Covington R, Tipler K, **Kimberlin DW**, Prichard MN: GenMark E-Sensor Respiratory Viral Panel in an Inpatient Pediatric Population. Clin. Infect. Dis. 2017.
5. Akhtar LN, Bowen CD, Renner DW, Pandey U, Della Fera AN, **Kimberlin DW**, Prichard MN, Whitley RJ, Weitzman MD, Szpara, ML. Genotypic and phenotypic diversity within the neonatal HSV-2 population. PNAS 2018.
6. Marsico C, Aban I, Kuo H, James SH, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Jester PM, Whitley RJ, **Kimberlin DW**, for the Collaborative Antiviral Study Group (CASG). Blood viral load is not clinically meaningful in symptomatic congenital cytomegalovirus disease. J. Infect. D. 2018.

## **PUBLICATIONS – REVIEW ARTICLES**

1. **Kimberlin DW**, Whitley RJ: Antiviral resistance – an emerging problem. Antiviral Res. 1995;26:365-368.\*
2. **Kimberlin DW**, Coen DM, Biron KK, Cohen JI, Lamb RA, McKinlay M, Emini EA, Whitley RJ: Molecular mechanisms of antiviral resistance. Antiviral Res. 1995;26:369-401.\*
3. **Kimberlin DW**, Spector SA, Hill EL, Biron KK, Hay AJ, Mayers DL, Whitley RJ: Assays for antiviral drug resistance. Antiviral Res. 1995;26:403-413.\*
5. **Kimberlin DW**, Kern ER, Sidwell RW, North TW, Whitley RJ: Models of antiviral

- resistance. *Antiviral Res.* 1995;26:415-422.\*
6. **Kimberlin DW**, Crumpacker CS, Straus SE, Biron KK, Drew WL, Hayden FG, McKinlay M, Richman DD, Whitley RJ: Antiviral resistance in clinical practice. *Antiviral Res.* 1995;26:423-438.\*
  7. **Kimberlin DW**, Couch RB, Galasso GJ, Richman DD, Whitley RJ: Research initiatives in studies of antiviral resistance and consensus points and recommendations. *Antiviral Res.* 1995;26:439-452.\*
  8. **Kimberlin DW**, Whitley RJ: Antiviral resistance: mechanisms, clinical significance, and future implications. *J. Antimicrob. Chemother.* 1996;37:403-421.\*
  9. Whitley RJ, **Kimberlin DW**: Treatment of viral infections during pregnancy and the neonatal period. *Clin. Perinatol.* 1997;24:267-283.\*
  10. **Kimberlin DW**: Rubella immunization. *Pediatr. Ann.* 1997;26(6):366-370.
  11. Whitley RJ, **Kimberlin DW**: Prophylaxis and treatment of herpesvirus infections in children. *Semin. Pediatr. Infect. Dis.* 1997;8(3):196-204.\*
  38. **Kimberlin DW**: Human herpesvirus-6 and -7: Identification of newly-recognized viral pathogens and their association with human disease. *Pediatr. Infect. Dis. J.* 1998;17:59-68.
  39. Whitley RJ, **Kimberlin DW**, Roizman B: Herpes simplex viruses. *Clin. Infect. Dis.* 1998;26:541-555.\*
  40. **Kimberlin DW**: Treatment of congenital and perinatal herpesvirus infections. *International Antiviral News* 1998;6:4-8.
  41. **Kimberlin DW**: Polymerase chain reaction and herpes simplex virus: Use of a diagnostic tool to re-define human disease. *HERPES* 1998;5(2):42-45.
  42. **Kimberlin DW**, Whitley RJ: Human herpesvirus-6: neurologic implications of a newly-described viral pathogen. *J. NeuroVirol.* 1998;4:474-485.\*
  43. Whitley RJ, **Kimberlin DW**: Viral encephalitis. *Pediatr. Rev.* 1999;20:192-198.\*
  44. **Kimberlin DW**: Neuroinvasion of human herpesviruses 6 and 7. *HERPES* 1999;6:60-63.
  45. **Kimberlin DW**, Malis DJ: Juvenile onset recurrent respiratory papillomatosis: Possibilities for successful antiviral therapy. *Antiviral Res.* 2000;45:83-93.\*



46. **Kimberlin DW:** Advances in the treatment of neonatal herpes simplex infection. *Rev. Med. Virol.* 2001;11:157-163.\*
47. **Kimberlin DW:** Acyclovir derivatives and other new antiviral agents. *Semin. Pediatr. Infect. Dis.* 2001;12:224-234.\*
48. **Kimberlin DW:** Meningitis in the neonate. *Curr. Treat. Options Neurol.* 2002;4:239-248.
49. **Kimberlin DW:** Antiviral therapy for cytomegalovirus infections in pediatric patients. *Semin. Pediatr. Infect. Dis.* 2002;13:22-30.\*
50. **Kimberlin DW:** Pharmacotherapy of recurrent respiratory papillomatosis. *Expert Opin. Pharmacother.* 2002;3:1091-1099.
51. **Kimberlin DW:** Herpes simplex virus infections in the neonatal period. *Infect. Med.* 2002;19:462-474.\*
52. **Kimberlin DW:** State of the Art: The use of PCR in the diagnosis of herpes simplex encephalitis [Perspectives, Contemporary Topics]. *MD Consult Infectious Disease.* October 30, 2002. Available at: <http://www.mdconsult.com>.
53. King JR, **Kimberlin DW**, Aldrovandi G, Acosta EP: Antiretroviral pharmacokinetics in the paediatric population. *Clin. Pharmacokinet.* 2002;41:1115-1133.\*
54. **Kimberlin DW:** Herpes simplex virus infections of the central nervous system. *Semin. Pediatr. Infect. Dis.* 2003;14:83-89.\*
55. Romero JR, **Kimberlin DW:** Viral infections of the central nervous system. *Clin. Lab. Med.* 2003;23(4):843-865.\*
56. **Kimberlin DW:** Neonatal herpes simplex infection. *Clin. Microbiol. Rev.* 2004;17(1):1-13.\*
57. **Kimberlin DW**, Rouse DJ: Genital herpes. *N. Engl. J. Med.* 2004;350(19):1970-1977.[PubMed: 15128897].\*
58. **Kimberlin DW:** Herpes simplex virus meningitis and encephalitis in neonates. *HERPES* 2004;11(Supplement 2):65A-76A.\*
59. **Kimberlin DW:** Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. *Antiviral Res.* 2004;63:141-151.\*
60. **Kimberlin DW**, Whitley RJ: Neonatal herpes: what have we learned? *Semin. Pediatr. Infect. Dis.* 2005;16:7-16.\*

61. Whitley RJ, **Kimberlin DW**: Herpes simplex encephalitis: children and adolescents. *Semin. Pediatr. Infect. Dis.* 2005;16:17-23.\*
62. **Kimberlin DW**: Antiviral therapies in children: Has their time arrived? *Pediatr. Clin. North Am.* 2005;52:837-867.\*
63. **Kimberlin DW**: Diagnosis of herpes simplex virus infections of the central nervous system. *Expert Rev. Mol. Diagn.* 2005;5:537-547.\*
64. **Kimberlin DW**: Herpes simplex virus infections in neonates and early childhood. *Semin. Pediatr. Infect. Dis.* 2005;16:271-281.\*
65. **Kimberlin DW**: Diagnosis of HSV in the era of PCR. *Concise Reviews in Pediatric Infectious Diseases (blue pages in Pediatr Infect Dis J)*. *Pediatr. Infect. Dis. J.* 2006;25(9):841-842.\*
66. **Kimberlin DW**: Herpes simplex virus infections in the newborn. *Semin. Perinatol.* 2007;31:19-25.\*
67. **Kimberlin DW**, Whitley RJ: Varicella-zoster virus vaccine for the prevention of herpes zoster. *N. Engl. J. Med.* 2007;356:1338-1343. PubMed PMID: 17392303\*
68. **Kimberlin DW**: Management of HSV encephalitis in adults and neonates (diagnosis, prognosis and treatment). *HERPES* 2007;14:11-16.\*
69. Nassetta L, **Kimberlin DW**, Whitley RJ: Treatment of congenital cytomegalovirus infection: Implications for future therapeutic strategies. *J. Antimicrob. Chemother.* 2009; 63:862–867. PubMed PMID:19287011; PubMed Central PMCID: PMC2667137\*
70. James SH, **Kimberlin DW**, Whitley RJ: Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. *Antiviral Research* 2009; 83:207-213. PubMed PMID:19414035; PubMed Central PMCID: PMC2748655\*
71. Acosta EP, **Kimberlin DW**: Determination of appropriate dosing of influenza drugs in pediatric patients. *Clin. Pharmacol. Therapeut. Clin Pharmacol Ther.* 2010;88(5):704-707. PMID: 20881956.\*
72. Pinninti SG, **Kimberlin DW**: Maternal and neonatal herpes simplex virus infections. *Am. J. Perinatol.* 2013;30(2):113-120.\* PubMed PMID: 23303485.
73. Pinninti SG, **Kimberlin DW**: Neonatal infectious diseases: neonatal HSV infection. *Pediatr. Clin. North Am.* 2013;60(2):351-365. PubMed PMID: 23481105.\*

74. Schlaudecker EP, Englund JA, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices February 2013 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2013;2(2):97-99.
75. **Kimberlin DW**: Acyclovir dosing in the neonatal period and beyond. *J. Pediatr. Infect. Dis. Soc.* 2013;2(2):179-182.
76. Schlaudecker EP, Englund JA, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices June 2013 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2013;2(4):309-311.
77. Schlaudecker EP, Sawyer MH, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices October 2013 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2014;3(1):1-3.
78. Pinninti SG, **Kimberlin DW**: Management of neonatal herpes simplex infection and exposure. *Arch. Dis. Child. Fetal Neonatal Ed.* 2014;99:F240-F244. PubMed PMID: 24589428.\*
79. James SH, Sawyer MH, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices February 2014 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2014;3(2):94-97.
80. James SH, Sheffield JS, **Kimberlin DW**: Mother to child transmission of herpes simplex virus. *J. Pediatr. Infect. Dis. Soc. NICHD Supplement*2014;3(Supplement 1):S19-S23.\*
81. James SH, Englund JA, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices June 2014 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2014;3(4):282-285.
82. Pinninti SG, **Kimberlin DW**: Preventing HSV in the newborn. *Clin. Perinatol.* 2014;41:945-955.\*
83. James SH, **Kimberlin DW**: HSV epidemiology and treatment. *Clin. Perinatol.* 2015;42(1):47-59.\*
84. Tam P-YI, Sawyer MH, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices February 2015 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2015;4(2):94-95.
85. James SH, **Kimberlin DW**: Neonatal HSV infection. *Infect. Dis. Clin. North Am.* 2015;29(3):391-400. PubMed PMID:26154662.\*
86. Tam P-YI, Sawyer MH, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices October 2015 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2016;5(1):3-

6. PubMed PMID: 26759500
87. James SH, **Kimberlin DW**: Advances in the prevention and treatment of congenital CMV. *Curr. Opin. Pediatr.* 2016;28:81–85\*
88. Schuster JE, Sawyer MH, O'Leary S, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices February 2016 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2016;5(2):101-104.
89. Schuster JE, O'Leary S, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices June 2016 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2016;5(4):349-355.
90. Marsico C, **Kimberlin DW**: Congenital cytomegalovirus infection: Advances and challenges in diagnosis, prevention, and treatment. *Ital. J. Pediatr.* 2017 Apr 17;43(1):38. doi: 10.1186/s13052-017-0358-8.
91. Schuster JE, Sawyer MH, O'Leary S, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices October 2016 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2017;6(2):111-115.
92. O'Leary ST, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices June 2017 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2017;6(4):311-316.
93. Poole C, **Kimberlin DW**: Antiviral drugs in newborns and children. *Pediatr. Clin. North Am.* 2017Dec;64(6):1403-1415. doi: 10.1016/j.pcl.2017.08.014. PMID: 29173793 [PubMed - in process]
94. Boppana SB, Britt WJ, Fowler K, Hutto SC, James SH, **Kimberlin DW**, Poole C, Ross SA, Whitley RJ. *J. Infect. Dis.* 2017;216(Suppl 10):S912-S918 <https://doi.org/10.1093/infdis/jix431>
95. Kabani N, **Kimberlin DW**: Neonatal herpes simplex virus infection. *NeoReviews.* *NeoReviews* 2018;19:e89.
96. Moodley A, Bradley JS, **Kimberlin DW**: Antiviral Treatment of Childhood Influenza: an Update. *Curr Opin Pediatr* 2018 Jun;30(3):438-447. doi: 10.1097/MOP.0000000000000618. PMID: 29745939
97. Pinninti SG, **Kimberlin DW**: Neonatal HSV infections. *Seminars in Perinatology.* 2018;42(3):168-175.
98. O'Leary ST, **Kimberlin DW**, Maldonado YA: Update from the Advisory Committee on Immunization Practices October 2017 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2018;7(2):93-99.

99. O'Leary ST, **Kimberlin DW**: Update from the Advisory Committee on Immunization Practices February 2018 Meeting. *J. Pediatr. Infect. Dis. Soc.* 2018 Jun 28. doi: 10.1093/jpids/piy050. [Epub ahead of print]

#### **PUBLICATIONS – REVIEW ARTICLES – In Preparation**

1. Poole C, **Kimberlin DW**: Antiviral Approaches for the Treatment of Herpes Simplex Virus Infections in Newborn Infants. *Annual Rev. Virol.*, Volume 5. September 2018.

#### **PUBLICATIONS – AAP COMMITTEE ON INFECTIOUS DISEASES STATEMENTS**

1. Committee on Infectious Diseases (Powell KR, Baltimore RS, Bernstein HH, Bocchini JA Jr, Bradley JS, Brady MT, Dennehy PH, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): Recommended childhood and adolescent immunization schedule – United States, 2006. *Pediatrics* 2006;117(1):239-244.
2. **Kimberlin DW**: VZIG discontinued; alternative available for VZV exposures. *AAP News* 2006;27(4):32-33.
3. Committee on Infectious Diseases (Long SS, Powell KR, Baltimore RS, Bernstein HH, Bocchini JA Jr, Bradley JS, Brady MT, Dennehy PH, Frenck RW Jr, **Kimberlin DW**, McMillan JA, Rubin LG): Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. *Pediatrics* 2006;117(3):965-978.
4. Committee on Infectious Diseases (Bradley JS, Powell KR, Baltimore RS, Bernstein HH, Bocchini JA Jr, Brady MT, Dennehy PH, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): The use of systemic fluoroquinolones. *Pediatrics* 2006;118(3):1287-1292.
5. Committee on Infectious Diseases (Dennehy PH, Bocchini JA Jr, Baltimore RS, Bernstein HH, Bradley JS, Brady MT, Fisher MC, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. *Pediatrics* 2007;119(1):171-181.
6. Committee on Infectious Diseases (Bocchini JA Jr, Baltimore RS, Bernstein HH, Bradley JS, Brady MT, Dennehy PH, Fisher MC, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): Recommended childhood and adolescent immunization schedule – United States, 2007. *Pediatrics* 2007;119(1):207-214.
7. **Kimberlin DW**: AAP Monitoring Supplies of Three Varicella-Containing Vaccines. *AAP News* 2007;28(4):10.
8. **Kimberlin DW**: New AAP Policy: Additional Dose of Varicella Vaccine Recommended

- for Children. AAP News 2007;28(5):1,8.
9. **Kimberlin DW**: Supply difficulties expected with MMRV. AAP News 2007;28(6).
  10. Committee on Infectious Diseases (Bernstein HH, Bocchini JA Jr, Baltimore RS, Bradley JS, Brady MT, Dennehy PH, Fisher MC, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): Prevention of influenza: Recommendations for influenza immunization of children, 2006-2007. Pediatrics 2007;119(4):846-851.
  11. Committee on Infectious Diseases (Bradley JS, Bocchini JA Jr, Baltimore RS, Bernstein HH, Brady MT, Dennehy PH, Fisher MC, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): Antiviral therapy and prophylaxis for influenza in children. Pediatrics 2007;119(4):852-860.
  12. Committee on Infectious Diseases (Frenck RW Jr, **Kimberlin DW**, Bocchini JA Jr, Baltimore RS, Bernstein HH, Bradley JS, Brady MT, Dennehy PH, Fisher MC, Long SS, McMillan JA, Rubin LG): Hepatitis A Vaccine Recommendations. Pediatrics 2007;120(1):189-199.
  13. Committee on Infectious Diseases (**Kimberlin DW**, Bocchini JA Jr, Baltimore RS, Bernstein HH, Bradley JS, Brady MT, Dennehy PH, Fisher MC, Frenck RW Jr, Long SS, McMillan JA, Rubin LG): Prevention of Varicella: Recommendations for Use of Varicella Vaccines in Children, Including a Recommendation for a Routine Two-Dose Varicella Immunization Schedule. Pediatrics 2007;120(1):221-231.
  14. Committee on Infectious Diseases (Bocchini JA Jr, Baltimore RS, Bernstein HH, Bradley JS, Brady MT, Dennehy PH, Fisher MC, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): Infection Prevention and Control in Pediatric Ambulatory Settings. Pediatrics 2007;120(3):650-665.
  15. Committee on Infectious Diseases (Bocchini JA Jr, Baltimore RS, Bernstein HH, Bradley JS, Brady MT, Dennehy PH, Fisher MC, Frenck RW Jr, **Kimberlin DW**, Long SS, McMillan JA, Rubin LG): Prevention of Human Papillomavirus Infection: Provisional Recommendations for Immunization of Girls and Women with Quadrivalent Human Papillomavirus Vaccine. Pediatrics 2007;120(3):666-668.
  16. Bocchini JA Jr., **Kimberlin DW**: Update on Shortages of Hib, Varicella-containing Vaccines. AAP News 2008;29(2):4.
  17. Committee on Infectious Diseases (Bocchini JA Jr, Bernstein HH, Bradley JS, Brady MT, Byington CL, Dennehy PH, Fisher MC, Frenck RW Jr, Glodé MP, Keyserling HL, **Kimberlin DW**, Long SS, Rubin LG): Recommended childhood and adolescent immunization schedule – United States, 2008. Pediatrics 2008;121(1):219-220.
  18. Committee on Infectious Diseases (Bernstein HH, Bocchini JA Jr, Bradley JS, Brady MT,

- Byington CL, Dennehy PH, Fisher MC, Frencck RW Jr, Glodé MP, Keyserling HL, **Kimberlin DW**, Long SS, Rubin LG): Prevention of influenza: Recommendations for influenza immunization of children, 2007-2008. *Pediatrics* 2008;121(4):e1016-e1031. PubMed PMID:18381500
19. **Kimberlin DW**: Zoster vaccines not just for children anymore. *AAP News* 2008;29(7):1,8.
  20. Pickering LK, Marano N, Bocchini JA, Angulo FJ, and Committee on Infectious Diseases (Bocchini JA Jr, Bernstein HH, Bradley JS, Brady MT, Byington CL, Dennehy PH, Fisher MC, Frencck RW Jr, Glodé MP, Keyserling HL, **Kimberlin DW**, Long SS, Rubin LG): Exposure to nontraditional pets at home and to animals in public settings: Risks to children. *Pediatrics* 2008;122(4):876-886.
  21. Committee on Infectious Diseases (Bernstein HH, Bocchini JA Jr, Bradley JS, Brady MT, Byington CL, Dennehy PH, Fisher MC, Frencck RW Jr, Glodé MP, Keyserling HL, **Kimberlin DW**, Orenstein WA, Rubin LG): Prevention of influenza: Recommendations for influenza immunization of children, 2008-2009. *Pediatrics* 2008;122(5):1135-1141. PubMed PMID:18779253
  22. Committee on Infectious Diseases (Bocchini JA Jr, Bernstein HH, Bradley JS, Brady MT, Byington CL, Dennehy PH, Fisher MC, Frencck RW Jr, Glodé MP, Keyserling HL, **Kimberlin DW**, Orenstein WA, Rubin LG): Recommended childhood and adolescent immunization schedule – United States, 2009. *Pediatrics* 2009;123(1):189-190. PubMed PMID:19117881
  23. Committee on Infectious Diseases (Dennehy PH, Bocchini JA Jr, Bernstein HH, Bradley JS, Brady MT, Byington CL, Fisher MC, Frencck RW Jr, Glodé MP, Keyserling HL, **Kimberlin DW**, Orenstein WA, Rubin LG): Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine. *Pediatrics* 2009;123(5):1412-1420. PubMed PMID:19332437
  24. **Kimberlin DW**: Ganciclovir may be used during intravenous acyclovir shortage. *AAP News* 2009;30(3):10.
  25. Committee on Infectious Diseases (Brady MT, Bocchini JA Jr, Bernstein HH, Bradley JS, Byington CL, Dennehy PH, Fisher MC, Frencck RW Jr, Glodé MP, Keyserling HL, **Kimberlin DW**, Orenstein WA, Rubin LG): Drinking Water from Private Wells and Risks to Children. *Pediatrics* 2009;123(6):1599-1603.
  26. Bocchini JA Jr., **Kimberlin DW**: Polio vaccine recommendations updated to reduce confusion, add clarity. *AAP News* 2009;30(9):8.
  27. Committee on Infectious Diseases (Bernstein HH, Bradley JS, Bocchini JA Jr, Brady MT, Byington CL, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**,

- Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommendations for the Prevention and Treatment of Influenza in Children, 2009-2010. *Pediatrics* 2009;124(4):1216-1226. PubMed PMID:19736264
28. **Kimberlin DW**, Bocchini JA Jr.: Monovalent vaccines no longer available for measles, mumps, and rubella. *AAP News* 2009;30(12):9.
  29. Committee on Infectious Diseases (Meissner HC, Bernstein HH, Bradley JS, Bocchini JA Jr, Brady MT, Byington CL, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections. *Pediatrics* 2009;124(6):1694-1701. PubMed PMID:19736258
  30. Committee on Infectious Diseases (Bocchini JA Jr, Bernstein HH, Bradley JS, Brady MT, Byington CL, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommended childhood and adolescent immunization schedule – United States, 2010. *Pediatrics* 2010;125(1):195-196. PubMed PMID:20048088
  31. **Kimberlin DW**: ACIP, AAP support choice of MMRV or separate MMR, varicella vaccines. *AAP News* 2010;31(1):10.
  32. Committee on Infectious Diseases (Bocchini JA Jr, Bernstein HH, Bradley JS, Brady MT, Byington CL, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommendations for the prevention of *Streptococcus pneumoniae* infections in infants and children: Use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). *Pediatrics* 2010;126(1):186-190. PubMed PMID: 20498180
  33. Committee on Infectious Diseases (Bocchini JA Jr, Bernstein HH, Bradley JS, Brady MT, Byington CL, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Cochlear implants in children: surgical site infections and prevention and treatment of acute otitis media and meningitis. *Pediatrics* 2010;126(2):381-391. PubMed PMID: 20660544
  34. Committee on Infectious Diseases (Bocchini JA Jr, Brady MT, Baltimore RS, Bernstein HH, Bradley JS, Byington CL, Dennehy PH, Fisher MC, Frenck RW Jr, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, McMillan JA, Orenstein WA, Rubin LG, Schutze GE, Willoughby RE): Head lice. *Pediatrics* 2010;126(2):392-403. PubMed PMID: 20660553
  35. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommendations for mandatory influenza immunization of all health care personnel. *Pediatrics*



- 2010;126(4):809-815.
36. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommendations for prevention and control of influenza in children, 2010, 2011. *Pediatrics* 2010;126(4):816-826.
  37. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommended childhood and adolescent immunization schedule – United States, 2011. *Pediatrics* 2011;127(2):387-388.
  38. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Rabies-prevention Policy Update: New reduced-dose schedule. *Pediatrics* 2011;127(4):785-787.
  39. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommendations for the Prevention of Perinatal Group B Streptococcal (GBS) Disease. *Pediatrics* 2011;128(3):611-616.
  40. Committee on Infectious Diseases (**Kimberlin DW**, Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Prevention of Varicella: Update of Recommendations for Use of Quadrivalent and Monovalent Varicella Vaccines in Children. *Pediatrics* 2011;128(3):630-632.
  41. **Kimberlin DW**: Updated recommendations for use of varicella vaccines in children. *AAP News* 2011;32(10):1,11.
  42. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Recommendations for Administering Hepatitis A Vaccine to Contacts of International Adoptees. *Pediatrics* 2011;128(4):803-804.
  43. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Poliovirus. *Pediatrics* 2011;128(4):805-808.

44. Committee on Infectious Diseases (Brady MT, Bernstein HH, Byington CL, Edwards K, Fisher MC, Glodé MP, Jackson MA, Keyserling HL, **Kimberlin DW**, Maldonado Y, Orenstein WA, Schutze GE, Willoughby RE): Policy Statement – Meningococcal Conjugate Vaccines Policy Update: Booster Dose Recommendations. *Pediatrics* 2011;128(4):1213-1218.
45. Bradley JS, Bernstein HH, **Kimberlin DW**, Brady MT: Antiviral therapy options critical for high-risk patients with influenza. *AAP News* 2012;33(12):12-13.
46. **Kimberlin DW**, Baley J, Committee on Infectious Diseases, Committee on Fetus and Newborn: Executive Summary: Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. *Pediatrics* 2013;131(2):383-386.
47. **Kimberlin DW**, Baley J, Committee on Infectious Diseases, Committee on Fetus and Newborn: Clinical Report: Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. *Pediatrics* 2013;131(2):e635-e646.
48. **Kimberlin DW**: AAP Clarifies Approach to Babies Born to Women with Genital Herpes Lesions. *AAP News* 2013;34(2):30.

#### **PUBLICATIONS – DHHS GUIDELINES**

1. Herpesvirus Working Group (**DWK is a member of the Working Group**), Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Published online at <http://www.aidsinfo.nih.gov/> June 18, 2008, and in *MMWR* April 10, 2009;58(RR04):1-198.
2. Pediatric Working Group (**DWK is a member of the Working Group**), Department of Health and Human Services Public Health Service / Infectious Diseases Society of America Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. Published online at <http://www.aidsinfo.nih.gov/> June 20, 2008, and in *MMWR* August 26, 2009;58(Early Release):1-166.
3. Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; and the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children (Bhattacharya D; Bohannon B; Clarke D.; Edwards KM; Esbenschade JC; Flynn P; Gaur A; Gigliotti F; Harrison G; Hobbs CV; **Kimberlin D**; Kleiman MB; Koumans EH; Kroger A; Levin MJ; Mack CL; Marais BJ; Maron G; McAuley J; Menzies HJ; Moscicki A; Narkewicz MR; Rutstein R; Seward J; Shimamura M; Steinbach WJ; Wilson GJ): Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric

Infectious Diseases Society, and the American Academy of Pediatrics. *Pediatr. Infect. Dis. J.* 2013; 32 (Supplement 2).

## **PUBLICATIONS – BOOKS**

1. American Academy of Pediatrics. Red Book: 2009 Report of the Committee on Infectious Diseases, 28<sup>th</sup> edition, Pickering LK, Baker CJ, **Kimberlin DW**, Long SS (eds), American Academy of Pediatrics (Elk Grove Village, IL), 2009.
2. American Academy of Pediatrics. Red Book: 2012 Report of the Committee on Infectious Diseases, 29<sup>th</sup> edition, Pickering LK, Baker CJ, **Kimberlin DW**, Long SS (eds), American Academy of Pediatrics (Elk Grove Village, IL), 2012.
3. American Academy of Pediatrics. Red Book: 2015 Report of the Committee on Infectious Diseases, 30<sup>th</sup> edition, **Kimberlin DW**, Brady MT, Jackson MA, Long SS (eds), American Academy of Pediatrics (Elk Grove Village, IL), 2015.

## **PUBLICATIONS – BOOK CHAPTERS**

1. **Kimberlin DW**, Whitley RJ. Herpes simplex viruses. In: Current Therapy of Infectious Disease, D Schlossberg (ed), Mosby-Year Book, Inc. (Philadelphia), pp. 494-498, 1996.
2. **Kimberlin DW**, Kimberlin DF, Whitley RJ. The treatment, management, and prevention of neonatal herpes simplex virus infections. In: Perinatal HSV Infections, LR Stanberry (ed), John Wiley & Sons, Limited (England), pp. 209-236, 1996.
3. **Kimberlin DW**, Plotkin SA. Vaccines for viral diseases with significant central nervous system manifestations. In: Infections of the Central Nervous System, 2nd edition, WM Scheld, RJ Whitley, DT Durack (eds), Lippincott-Raven Publishers, Limited (New York), pp. 983-1012, 1997.
4. **Kimberlin DW**. Rubella virus. In: Clinical Virology, DD Richman, RJ Whitley, FG Hayden (eds), Churchill Livingstone Inc. (New York), pp. 1257-1272, 1997.
5. **Kimberlin DW**, Whitley RJ. Herpes simplex viruses. In: Current Therapy in Adult Medicine, 4th edition, JP Kassirer, HL Greene (eds), Mosby-Year Book, Inc. (Philadelphia), pp. 327-330, 1997.
6. **Kimberlin DW**, Gnann JW. Infection and disease due to human herpesvirus-6 and -7. In: AIDS Therapy, R Dolin, H Masur, M Saag (eds), Churchill Livingstone, Inc. (New York), pp. 507-515, 1999.
7. **Kimberlin DW**, Whitley RJ. Trattamento, gestione e prevenzione dell'infezione neonatale da virus herpes simplex. In: Herpes Genitale: Il Virus, L'Infezione e il Controllo, A Volpi (ed), Il Pensiero Scientifico Editore, Roma (Italy), pp. 79-102, 2000.

8. **Kimberlin DW.** Cough and subjective fever in a 7-month-old girl. In: Pediatrics: A Problem-Based Review, FD Burg, VC Vaughan III, KG Nelson (eds), W.B. Saunders Company (United States), pp. 189-192, 2001.
9. **Kimberlin DW, Whitley RJ.** Herpes simplex viruses. In: Current Therapy of Infectious Disease, 2nd Edition, D Schlossberg (ed), Mosby, Inc. (St. Louis, Missouri), pp. 586-590, 2001.
10. **Kimberlin DW, Whitley RJ.** Herpes simplex virus infections. In: Textbook of Clinical Pediatrics, A Elzouki, HA Al-Harfi, HM Nazer (eds), Lippincott Williams & Wilkins (Philadelphia PA), pp. 362-371, 2001.
11. **Kimberlin DW.** Antiviral agents and therapy. In: Textbook of Clinical Pediatrics, A Elzouki, HA Al-Harfi, HM Nazer (eds), Lippincott Williams & Wilkins (Philadelphia PA), pp. 296-309, 2001.
12. **Kimberlin DW.** Rubella virus. In: Clinical Virology, 2nd Edition, DD Richman, RJ Whitley, FG Hayden (eds), ASM Press (Washington, D.C.), pp. 1211-1225, 2002.
13. Whitley RJ, **Kimberlin DW.** Antiviral agents. In: Gellis and Kagan's Current Pediatric Therapy, 17<sup>th</sup> Edition, FD Burg, JR Ingelfinger, RA Polin, AA Gershon (eds), W.B. Saunders Company (Philadelphia PA), pp. 244-256, 2002.
14. **Kimberlin DW, Prober CG.** Antiviral agents. In: Principles and Practice of Pediatric Infectious Diseases, 2nd edition, SS Long, LK Pickering, CG Prober (eds), Churchill Livingstone (Philadelphia PA), pp. 1527-1547, 2003.
15. **Kimberlin DW, Gnann JW.** Infection and disease due to human herpesvirus-6 and -7. In: AIDS Therapy, 2nd Edition, R Dolin, H Masur, M Saag (eds), Churchill Livingstone, Inc. (New York), pp. 604-612, 2003.
16. **Kimberlin DW, Gershon AA.** Vaccines for viral diseases with significant central nervous system manifestations. In: Infections of the Central Nervous System, 3rd edition, WM Scheld, RJ Whitley, C Marra (eds), Lippincott Williams & Wilkins (Philadelphia), pp. 879-897, 2004.
17. Prober CG, **Kimberlin DW.** Antiviral drugs. In: Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice, 3rd edition, SJ Yaffe, JV Aranda (eds), Lippincott Williams & Wilkins (Philadelphia), pp. 475-503, 2005.
18. **Kimberlin DW.** Herpes simplex virus. In: Infectious Disease: Congenital and Perinatal Infections: A Concise Guide to Diagnosis, C Hutto (ed), Humana Press (Totowa, New Jersey), pp. 63-72, 2005.

19. **Kimberlin DW.** Herpes Simplex Virus. In: Current Pediatric Therapy, 18<sup>th</sup> Edition, FD Burg, JR Ingelfinger, RA Polin, AA Gershon (eds), Elsevier Inc. (Philadelphia PA), pp. 772-778, 2006.\*
20. **Kimberlin DW,** Whitley RJ. Antiviral therapy of HSV-1 and -2. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, AM Arvin, G Campadelli-Fiume, E Mocarski, PS Moore, B Roizman, RJ Whitley, K Yamanishi (eds), Cambridge University Press (New York), pp. 1153-1174, 2007.
21. **Kimberlin DW.** Immunotherapy of HSV Infections – Antibody Delivery. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, AM Arvin, G Campadelli-Fiume, E Mocarski, PS Moore, B Roizman, RJ Whitley, K Yamanishi (eds), Cambridge University Press (New York), pp. 1332-1337, 2007.
22. Whitley RJ, **Kimberlin DW,** Prober CG. Herpes Simplex Virus-1 and -2: Pathogenesis and Disease. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, AM Arvin, G Campadelli-Fiume, E Mocarski, PS Moore, B Roizman, RJ Whitley, K Yamanishi (eds), Cambridge University Press (New York), pp. 589-601, 2007.\*
23. **Kimberlin DW.** Antiviral agents. In: Principles and Practice of Pediatric Infectious Diseases, 3rd edition, SS Long, LK Pickering, CG Prober (eds), Elsevier, Inc. (New York, NY), pp. 1470-1488, 2008.
24. **Kimberlin DW,** Gnann JW. Infection and disease due to human herpesvirus-6 and -7. In: AIDS Therapy, 3rd Edition, R Dolin, H Masur, M Saag (eds), Elsevier, Inc. (Philadelphia), pp. 899-909, 2008.
25. **Kimberlin DW.** Antiviral agents. In: Pediatric Infectious Diseases: The Requisites in Pediatrics, J Bergelson, S Shah, T Zaoutis, (eds), Elsevier Science/Mosby (Philadelphia), pp. 29-36, 2008.
26. **Kimberlin DW,** Whitley RJ. Herpes simplex virus 1 and 2. In: Clinical Infectious Diseases, D Schlossberg (ed), Cambridge University Press, NY, pp. 1275-1280, 2008.
27. **Kimberlin DW.** Rubella virus. In: Clinical Virology, 3rd Edition, DD Richman, RJ Whitley, FG Hayden (eds), ASM Press (Washington, D.C.), pp. 1275-1289, 2009.
28. Whitley RJ, Acosta EP, **Kimberlin DW.** Antiviral drugs: Treatment of the fetus and newborn. In: Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice, 4th edition, SJ Yaffe, JV Aranda (eds), Lippincott Williams & Wilkins (Philadelphia), pp. 519-532, 2011.\*
29. **Kimberlin DW,** Palazzi DL, Whitley RJ. Therapy for perinatal and neonatal infections. In: Rudolph's Pediatrics, 22<sup>nd</sup> Edition, Rudolph CD, Rudolph AM, Lister G, First LR, Gershon AA (eds), McGraw Hill Medical (New York, NY), pp. 902-912, 2011.

30. **Kimberlin DW.** Herpes simplex virus infections. In: Textbook of Clinical Pediatrics, 2nd edition, A Elzouki, HA Al-Harfi, B Stapleton, W Oh, R Whitley (eds), Springer, pp. 1167-1180, 2011.\*
31. **Kimberlin DW.** Human herpesviruses type 6 and type 7. In: Textbook of Clinical Pediatrics, 2nd edition, A Elzouki, HA Al-Harfi, B Stapleton, W Oh, R Whitley (eds), Springer, pp. 1181-1184, 2011.
32. **Kimberlin DW.** Antiviral therapy. In: Textbook of Clinical Pediatrics, 2nd edition, A Elzouki, HA Al-Harfi, B Stapleton, W Oh, R Whitley (eds), Springer, pp. 903-921, 2011.\*
33. Guffey B, **Kimberlin DW.** Host defense mechanisms against viruses. In: Fetal and Neonatal Physiology, 4<sup>th</sup> Edition, RA Polin, WW Fox, SH Abman (eds), Elsevier/Saunders, pp. 1570-1595, 2011.
34. **Kimberlin DW.** Neonatal viral and protozoal brain infections. In: Neurology – Neonatology Questions and Controversies, 2nd edition, Perlman J (ed), Elsevier Saunders, pp. 203-217, 2012.\*
35. **Kimberlin DW.** Antiviral agents and therapy. In: Principles and Practice of Pediatric Infectious Diseases, 4th edition, SS Long, LK Pickering, CG Prober (eds), Elsevier, Inc. (New York, NY), pp. 1502-1518, 2012.\*
36. James SH, **Kimberlin DW.** Herpes simplex virus. In: Transplant Infections. Singh N. (ed), ESun Technologies LLC, Pittsburgh, PA, pp. 56-70, 2012.\*
37. Assi M, James SH, **Kimberlin DW.** Varicella zoster virus. In: Transplant Infections. Singh N. (ed), ESun Technologies LLC, Pittsburgh, PA, pp. 46-55, 2012.\*
38. **Kimberlin DW.** Vaccines for viral diseases with significant central nervous system manifestations. In: Infections of the Central Nervous System, 4th edition, WM Scheld, RJ Whitley, CM Marra (eds), Wolters Kluwer Health (Philadelphia), pp. 859-875, 2014.
39. **Kimberlin DW,** Gutierrez KM. Herpes Simplex Virus infection. In: Remington & Klein's Infectious Diseases of the Fetus and Newborn Infant, 8th edition, CB Wilson, V Nizet, YA Maldonado, JS Remington, JO Klein (eds), Elsevier Saunders (Philadelphia), pp. 843-865, 2016.
40. **Kimberlin DW.** Rubella virus. In: Clinical Virology, 4th Edition, DD Richman, RJ Whitley, FG Hayden (eds), ASM Press (Washington, D.C.), pp. 1381-1393, 2017.
41. **Kimberlin DW,** Prober CG. Introduction to Herpesviridae. In: Principles and Practice of Pediatric Infectious Diseases, 5th edition, SS Long, CG Prober, M Fischer (eds),

Elsevier, Inc. (Philadelphia, PA), pp. 1055, 2018.

42. **Kimberlin DW**, Prober CG. Herpes simplex virus. In: Principles and Practice of Pediatric Infectious Diseases, 5th edition, SS Long, CG Prober, M Fischer (eds), Elsevier, Inc. (Philadelphia, PA), pp. 1056-1065, 2018.
43. **Kimberlin DW**. Antiviral agents and therapy. In: Principles and Practice of Pediatric Infectious Diseases, 5th edition, SS Long, CG Prober, M Fischer (eds), Elsevier, Inc. (Philadelphia, PA), pp. 1551-1567, 2018.
44. James SH, Gutierrez KM, **Kimberlin DW**. Neurological sequelae of congenital and perinatal infections. In: Fetal and Neonatal Brain Injury, 5th edition, Stevenson DK, Benitz WE, Sunshine P, Hintz SR, Druzin ML (eds), Cambridge University Press, pp. 501-522, 2018.
45. Kabani N, **Kimberlin DW**. Herpes simplex virus. In: Neonatal Infections: Pathogenesis, Diagnosis, and Management, Cantey JB (ed), Springer Nature (Cham, Switzerland), pp. 119-126, 2018.

#### **PUBLICATIONS - BOOK CHAPTERS - In Press**

1. Rha B, **Kimberlin DW**, Whitley RJ: Antiviral therapy. In: Lennette's Laboratory Diagnosis of Viral Infections, 4th edition, Jerome K (ed), Informa Healthcare (New York, NY), 2014.
2. **Kimberlin DW**. Herpes Simplex Virus. In: Antimicrobial Therapy and Vaccines, Volume I: Microbes, 3<sup>rd</sup> Edition, VL Yu, R Weber, D Raoult, JH Rex, RW Shafer, NJ White, JJ Treanor, MH Seenivasan (eds), E Sun Technologies, LLC, 2014.\*
3. Price N, **Kimberlin DW**. Chickenpox. In: Textbook of Pediatric Care, 2nd edition, McInerny TK, Adam HM, Campbell DE (eds), 2013.

#### **PUBLICATIONS – BOOK CHAPTERS – Submitted**

1. Kabani N, **Kimberlin DW**. Neonatal Herpes Simplex Virus Infection. In: Infectious Disease and Pharmacology, Benitz W and Smith B (eds), Elsevier, 2017.
2. Kabani N, **Kimberlin DW**. Neonatal Herpes Simplex Virus, Congenital Cytomegalovirus, and Congenital Zika Virus Infections. In: Neurology – Neonatology Questions and Controversies, 3rd edition, Perlman J (ed), Elsevier, 2017.
3. Poole C, **Kimberlin DW**. Antiviral Agents. In: Pediatric Practice: Infectious Diseases, 2nd edition, Shah S (ed), McGraw-Hill, 2017.
4. James SH, **Kimberlin DW**. Cutaneous manifestations of congenital and acquired

infections in the neonate. In: Harper's Textbook of Pediatric Dermatology, 4th Edition, P Hoeger, A Yan, V Kinsler, J Harper, A Oranje (eds), Wiley, 2017.

## **PUBLICATIONS – BOOK CHAPTERS – In Preparation**

1. Healy CM, **Kimberlin DW**, Palazzi DL. Therapy for perinatal and neonatal infections. In: Rudolph's Pediatrics, 23<sup>rd</sup> Edition, Kline MW, Blaney S, Giardino AP, Orange JS, Penny DJ, Schutze GE, Shekerdemian LS (eds), McGraw Hill (New York, NY), 2016.
2. Poole C, **Kimberlin DW**. Herpes simplex virus infections. In: Rudolph's Pediatrics, 23<sup>rd</sup> Edition, Kline MW, Blaney S, Giardino AP, Orange JS, Penny DJ, Schutze GE, Shekerdemian LS (eds), McGraw Hill (New York, NY), 2016.
3. Poole C, **Kimberlin DW**. Varicella-zoster virus infections. In: Rudolph's Pediatrics, 23<sup>rd</sup> Edition, Kline MW, Blaney S, Giardino AP, Orange JS, Penny DJ, Schutze GE, Shekerdemian LS (eds), McGraw Hill (New York, NY), 2016.

## **EDITORIALS AND COMMENTARIES**

1. **Kimberlin DW**: Neonatal HSV infections: the global picture. *HERPES* 2004;11(2):31-32.
2. **Kimberlin DW**: Commentary on "Evaluation of cytomegalovirus Infections transmitted via breast milk in preterm infants with a real-time polymerase chain reaction assay," published by Yasuda et al. in *Pediatrics* 2003;111:1333-1336. 2005 Year Book of Pediatrics, JA Stockman III (ed), Mosby – Year Book (Philadelphia), pp. 257-258, 2005 (January).
3. **Kimberlin DW**: When Should You Initiate Acyclovir Therapy in a Neonate? (Commentary on "The Prevalence of Neonatal Herpes Simplex Virus Infection Compared with Serious Bacterial Illness in Hospitalized Neonates," published by Caviness et al. in *Journal of Pediatrics* 2008). *J Pediatr* 2008;153:155-156. PubMed PMID:18639724
4. **Kimberlin DW**: Influenza Antiviral Drugs: Use Them Then Lose Them. *Infectious Diseases in Children* 2009;22(3):3-4.
5. **Kimberlin DW**: 2010 Distinguished Physician Award Presented to Richard J. Whitley, M.D. *Pediatric Infectious Disease Journal* 2010;29(9):790-791.
6. **Kimberlin DW**: Control of Varicella Disease, Version 2.0 (Commentary on "Effectiveness of Two Doses of Varicella Vaccine in Children" published by Shapiro et al. in *Journal of Infectious Diseases* 2011). *J Infect Dis* 2011;203:297-299.
7. **Kimberlin DW**: The Wars of the World: Saving Lives Through Vaccination. *Infectious Diseases in Children* 2011;24(10):8.



8. **Kimberlin DW:** If Not Vaccination, Then What? *AAP News* 2012;33:1.
9. Englund J, Karron R, Dennehy P, **Kimberlin D:** In Memoriam: Tribute to Caren Hall. *J Pediatr Infect Dis Soc* 2013;2(2):93-96.
10. Meissner HC, **Kimberlin DW:** RSV Immunoprophylaxis: Does the Benefit Justify the Cost? *Pediatrics* 2013;132(5):915-918. PubMed PMID: 24127478.
11. **Kimberlin DW:** The Scarlet H. *J. Infect. Dis.* 2014;209:315-317. PubMed PMID: 24136793.
12. James SH, **Kimberlin DW:** Quantitative Herpes Simplex Virus Concentrations in Neonatal Infection. *J. Pediatr.* 2015;166(4):793-795. PubMed PMID: 25662831.
13. Steinberg I, **Kimberlin DW:** Acyclovir dosing and acute kidney injury: deviations and direction. *J. Pediatr.* 2015;166(6):1341-1344. PubMed PMID: 25890674
14. **Kimberlin DW,** Aban I, Acosta EP: Authors reply to three letters to the Editor regarding article entitled “Valganciclovir for symptomatic congenital cytomegalovirus disease” (*N. Engl. J. Med.* 2015;372(10):933-943. PubMed PMID: 25738669). *N. Engl. J. Med.* 2015;372(25):2463.
15. **Kimberlin DW:** Sequelae Following Postnatally Acquired Cytomegalovirus Infection in Micropremies: Back To the Future. *JAMA Pediatr.* 2015 Dec;169(12):e153841. PMID: 26642119
16. Grosse SD, Dollard SC, **Kimberlin DW:** Targeted Screening for Congenital Cytomegalovirus Following Newborn Hearing Screening: What Comes Next? *Pediatrics* 2017 Feb;139(2). pii: e20163837. doi: 10.1542/peds.2016-3837.
17. **Kimberlin DW:** Why neonatal herpes matters. *The Lancet Global Health* 2017;5(3):e234-e235. doi: 10.1016/S2214-109X(17)30047-5. Epub 2017 Jan 31
18. Dilley S, Scarinci I, **Kimberlin D,** Straughn JM Jr.: Preventing HPV-related cancers – we are all in this together. *Am. J. Obstet. Gynecol.* 2017 Jun;216(6):576-579.e1. doi: 10.1016/j.ajog.2017.02.026. Epub 2017 Feb 21.
19. **Kimberlin DW,** Poole CL: Assessing the febrile child for serious infection – a step closer to meaningful rapid results. *Pediatrics* 2017 Oct;140(4). pii: e20171210. doi: 10.1542/peds.2017-1210. Epub 2017 Sep 13.
20. Uyeki T, Penttinen P, Catchpole M, Pebody R, Zambon M, Dunning J, Watson J, Bernstein H, Munoz FM, **Kimberlin DW,** Beigi R, Riley L, Pavia A, Powderly W, Spearman P, Shindo N. Response to Mark H. Ebell (Letter to the Editor in response to

an editorial published on July 12, 2017, entitled “WHO downgrades status of oseltamivir”). *British Medical Journal* 2017;358;j3266.

21. Mahant S, Berry JG, **Kimberlin DW**: Neonatal HSV disease: Balancing the low incidence with the need to treat promptly. *Pediatrics* 2018 Jan 3. pii: e20173647. doi: 10.1542/peds.2017-3647. [Epub ahead of print]
22. Ross S, Long SS, **Kimberlin DW**: Closer to universal newborn screening for congenital CMV, but far away from antiviral therapy for all infected infants. *J Pediatr* 2018 Apr 24. pii: S0022-3476(18)30474-8. doi: 10.1016/j.jpeds.2018.03.062. [Epub ahead of print]
23. **Kimberlin DW**: The Tail Wagging the Dog (Or the Challenges Faced When the Financing of Medicine Gets Ahead of the Science of Medicine). *J Clin Microbiol* 2018 Jul 18. pii: JCM.00904-18. doi: 10.1128/JCM.00904-18. [Epub ahead of print]

#### **PUBLICATIONS – ABSTRACTS**

1. **Kimberlin DW**, McCracken GH, Jr., Nisen PD: Mechanism of dexamethasone action in bacterial meningitis: dexamethasone (DXM) destabilizes interleukin-1 $\beta$  mRNA in the human astrocytoma cell line U-373MG. *Infectious Disease Society of America, Orlando, FL; Clin. Infect. Dis.* (1994) 19: 614; #304.
2. **Kimberlin DW**, Kimberlin DF, Andrews WW, Lakeman FD, DuBard MB, Soong SJ, Whitley RJ: Neonatal characteristics of infants born to women shedding herpes simplex virus (HSV) proximate to delivery. *International Herpes Management Forum (IHMF), San Francisco, CA; 1994.*
3. Kimberlin DF, **Kimberlin DW**, Andrews WW, Lakeman FD, Goldenberg RL, Whitley RJ: Prevalence of herpes simplex virus shedding in pregnancy. *Society of Perinatal Obstetricians, Atlanta, GA; Amer. J. Obstet. Gynec.* (1995) 172: 306; #161.
4. **Kimberlin DW**, Kimberlin DF, Andrews WW, Lakeman FD, DuBard MB, Soong SJ, Whitley RJ: Maternal and neonatal effects of genital herpes simplex virus (HSV) shedding proximate to delivery. *Society for Pediatric Research, San Diego, CA; Pediatr. Res.* (1995) 37: 179A; #1062.
5. **Kimberlin DW**, Lakeman FD, Whitley RJ, The NIAID Collaborative Antiviral Study Group (CASG): Application of the polymerase chain reaction (PCR) to the diagnosis and management of neonatal herpes simplex virus (HSV) disease. *35<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA; 1995; Abstract H5.*
6. **Kimberlin DW**, Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, Dankner W, Spector SA, Starr S, Pass RF, Stagno S, Britt WJ, Alford C, Soong SJ, and

- the NIAID Collaborative Antiviral Study Group: Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. 6<sup>th</sup> International Cytomegalovirus Workshop, Perdido Beach Resort, Orange Beach, Alabama; 1997; Abstract 55.
7. Johnson L, Laughlin C, Sawyer L, Gaither T, Gnann J, **Kimberlin D**, Whitley R: CASG: An established collaborative network for performance of multicentered clinical trials including chronic hepatitis B and C. American Association for the Study of Liver Diseases, Chicago, IL; June, 1997.
  8. **Kimberlin DW**, Jacobs RF, Powell DA, Corey L, Gruber W, Rathore M, Bradley J, Diaz P, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, Sierra T, Lin CY, Soong SJ, Lakeman FD, Whitley RJ, and the NIAID Collaborative Antiviral Study Group (CASG): The Safety and Efficacy of High-Dose (HD) Acyclovir (ACV) in Neonatal Herpes Simplex Virus (HSV) Infections. Society for Pediatric Research, San Francisco, CA; *Pediatr. Res.* (1999) 37: 165A; #963.
  9. **Kimberlin DW**, Lin CY, Sánchez P, Demmler G, Dankner W, Shelton M, Edwards K, Jacobs RF, Robinson J, Wright J, Lakeman FD, Kiell JM, Soong SJ, Whitley RJ, and the NIAID Collaborative Antiviral Study Group (CASG): Ganciclovir (GCV) Treatment of Symptomatic Congenital Cytomegalovirus (CMV) Infections: Results of a Phase III Randomized Trial. 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada; 2000; Abstract 1942.
  10. **Kimberlin DW**, Whitley RJ, for the NIAID Collaborative Antiviral Study Group (CASG): Ganciclovir Therapy for Congenital Cytomegalovirus Disease: Results of a Phase III Randomized Study. 8<sup>th</sup> International Cytomegalovirus Workshop, Asilomar Conference Grounds, Pacific Grove, Monterey Peninsula, California; May 20-25, 2001.
  11. Bradford RD, **Kimberlin DW**, Lakeman FD, Cloud G, Boppana SB, Britt WJ, Sánchez P, Demmler G, Dankner W, Shelton M, Jacobs RF, Whitley RJ, and the NIAID Collaborative Antiviral Study Group. Baseline viremia in congenital cytomegalovirus (CMV) infection correlates with clinical outcome. 39<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), San Francisco, CA; October 26, 2001.
  12. **Kimberlin DW**. Vertical transmission of HSV. 18<sup>th</sup> International Union Against Sexually Transmitted Diseases (IUSTI) Europe Congress on Sexually Transmitted Diseases, Vienna, Austria; *International Journal of STD & AIDS* (2002) 13 (Suppl 1): 60; # SAT12.
  13. Bonner AB, Talley L, Monroe KW, Klasner AE, **Kimberlin DW**. Effect of rapid influenza testing in the pediatric emergency department on patient management and outcomes. Southern Society for Pediatric Research Annual Meeting. New Orleans, LA, February 20-22, 2003. (Dr. Bonner was recipient of SSPR Clinical Young Investigator Award)

14. Bonner AB, Talley L, Monroe KW, Klasner AE, **Kimberlin DW**. Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department. Ambulatory Pediatric Association Annual Meeting. Seattle, WA, May 6, 2003.
15. **Kimberlin D**, Cloud G, Lakeman F, Jacobs R, Gutierrez K, Powell D, Corey L, Whitley R, for the NIAID Collaborative Antiviral Study Group (CASG). Serum Polymerase Chain Reaction (PCR) May Not Diagnose Neonatal Herpes Simplex Virus (HSV) Disease. 42<sup>nd</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Boston, MA; October 2, 2004; Abstract 992.
16. Oliver SE, Cloud G, Whitley R, **Kimberlin D**. Effect of Ganciclovir Therapy on Neurodevelopmental Outcomes in Symptomatic Congenital Cytomegalovirus Disease Involving the Central Nervous System: A Randomized, Controlled Trial. University of Alabama at Birmingham Medical Student Research Awards Day (Selected as the awardee for Outstanding Research Related to Pediatrics), October 18, 2005.
17. Oliver S, Cloud G, Sánchez P, Demmler G, Dankner W, Shelton M, Jacobs R, Vaudry W, Pass R, Soong S, Whitley R, **Kimberlin D**. Effect of Ganciclovir (GCV) Therapy on Neurodevelopmental Outcomes in Symptomatic Congenital Cytomegalovirus (CMV) Infections Involving the Central Nervous System (CNS): A Randomized, Controlled Study. Society for Pediatric Research (SPR), San Francisco, California, April 29, 2006; Abstract # 752908.
18. Shalabi M, Abughali N, Abzug M, Bradley J, Cloud G, Englund J, Griffin J, Guzman-Cottrill J, Jacobs R, Jester P, Lang D, Leach C, Ramilo O, Robinson J, Romero J, Shelton M, Storch G, Wade K, Whitley R, and **Kimberlin D**, for the NIAID Collaborative Antiviral Study Group (CASG). Safety of Oseltamivir vs. Amantadine or Rimantadine in Children Under 1 Year of Age. 45<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America (IDSA), San Diego, California, October 7, 2007; Abstract # 1225.
19. Benner K, Worthington M, Hayes L, Sims P, Searcy H, Bryant M, **Kimberlin D**. Daptomycin pharmacokinetics in a pediatric patient with methicillin-resistant *Staphylococcus aureus* endocarditis. American College of Clinical Pharmacy Spring Practice and Research Forum. Phoenix, AZ. April 6-9, 2008.
20. **Kimberlin D**, Acosta E, Sánchez P, Ampofo K, Vanchiere J, Englund J, Sood S, Lang D, Caserta M, Abzug M, Abughali N, Michaels M, Spigarelli M, Wan W, Jester P, Griffin J, Whitley R, for NIAID Collaborative Antiviral Study Group (CASG). Oseltamivir (OST) and OST Carboxylate (CBX) Pharmacokinetics (PK) in Infants: Interim Results from a Multicenter Trial. 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 31, 2009; Abstract #1041.
21. James SH, Hartline CB, Daily SL, Frederick SL, **Kimberlin DW**, Whitley RJ, Prichard

- MN. Genotypic resistance testing of cytomegalovirus DNA in congenitally infected infants after 6 weeks of treatment with ganciclovir/valganciclovir. 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 31, 2009; Abstract #711.
22. Jester PM, Griffin J, Bowers MW, Branscum S, Gnann J, **Kimberlin D**, Whitley R. The Need for Universal Institutional Review Boards (IRB) for Emergent Infections. 47<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 31, 2009; Abstract #1225.
23. Pinninti SG, Feja KN, **Kimberlin DW**, Leach CT, Conrad DA, McCarthy CA, Tolan RW, Jr. Neonatal herpes disease despite maternal antenatal antiviral suppressive therapy: A multicenter case series. 2010 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Vancouver, British Columbia, May 1-4, 2010; Abstract # 685.
24. Pinninti SG, Feja KN, **Kimberlin DW**, Leach CT, Conrad DA, McCarthy CA, Tolan RW, Jr. Neonatal herpes disease despite maternal antenatal antiviral suppressive therapy: A multicenter case series of the first such infants reported. 48<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, October 22, 2010; Abstract #1841.
25. **Kimberlin DW**, Whitley RJ, Wan W, Powell DA; Storch G, Ahmed A, Palmer A, Sánchez PJ, Jacobs RJ, Bradley JS, Robinson JL, Shelton M, Dennehy PH, Leach C, Rathore M, Abughali N, Wright P, Frenkel LM, Brady RC, Van Dyke R, Weiner LB, Guzman-Cottrill J, McCarthy CA, Griffin J, Jester P, Parker M, Lakeman FD, Kuo H, Lee CH, Cloud GA, for the NIAID Collaborative Antiviral Study Group. Impact of oral acyclovir suppression on neurodevelopmental outcomes and skin recurrences following neonatal herpes simplex virus disease. 48<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, October 22, 2010; Abstract #2977.
26. Kankirawatana P, Lakeman F, Kim H, Blount J, Rozzelle C, **Kimberlin D**. Human herpesvirus-6 (HHV6) and children with medically refractory epilepsy. 64<sup>th</sup> Annual Meeting of the American Epilepsy Society, San Antonio, Texas, December 5, 2010; Abstract # 2.010.
27. Jester PM, Griffin J, Branscum S, Acosta A, **Kimberlin D**, Whitley R. Meeting regulatory hurdles for emergent infections – Lessons from 2009 H1N1 influenza. Infectious Diseases Society of America Seasonal and Pandemic Influenza Meeting 2011, Arlington Virginia, January 27-28, 2011.
28. James SH, **Kimberlin DW**, Hartline CB, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Whitley RJ, Prichard MN. Longitudinal Assessment of Genotypic Resistance by Deep Sequencing of Cytomegalovirus DNA in Congenitally Infected Infants Treated with Valganciclovir. 49<sup>th</sup> Annual Meeting of The Infectious Diseases Society of America

- (IDSA), Boston, Massachusetts, October 20-23, 2011; Abstract #1215.
29. Wiltrakis SM, Cloud GA, Whitley RJ, Sánchez PJ, Ampofo K, Lang D, Ashouri N, Vanchiere JA, Abzug MJ, Abughali N, Caserta MT, Englund JA, Sood SK, Spigarelli MG, Bradley JS, Lew J, Michaels MG, Jester PM, **Kimberlin DW**. Predictors of Influenza Disease Severity and Resolution in Infants: Results of a National Collaborative Trial. Society for Pediatric Research (SPR), Boston, Massachusetts, April 28, 2012; Abstract #752603.
  30. Kamal M, Acosta E, **Kimberlin D**, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sánchez P, Ampofo K, Whitley R, Rayner C. Population pharmacokinetics define dosing recommendations of oseltamivir in neonates and infants with influenza. Options for the Control of Influenza, Cape Town, South Africa, September 5-10, 2013; Poster #4995.
  31. **Kimberlin DW**, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels M, Sood SK, Woods C, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, Tolan RW, DeBiasi RL, Han J-Y, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths P, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Aban I, Acosta EP, Whitley RJ, for the NIAID Collaborative Antiviral Study Group (CASG). Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: Results of a Phase III, randomized, double-blind, placebo-controlled, multinational study. IDWeek 2013 (annual meeting of the Pediatric Infectious Diseases Society, the Infectious Diseases Society of America, the HIV Medical Association, and the Society for Healthcare Epidemiology of America), San Francisco, CA, October 5, 2013; Late-Breaker Abstract #43178.
  32. Potter J, Oliver S, Covington R, Tipler K, **Kimberlin D**, Prichard M. Comparison of the Genmark eSensor Respiratory Viral Panel to Direct Fluorescence and Culture in a Pediatric Population. 30<sup>th</sup> Annual Clinical Virology Symposium of the American Society for Microbiology, Daytona Beach, Florida, April 27, 2014; Abstract #1121.
  33. Hough-Telford C, **Kimberlin DW**, O'Connor KG. Vaccine Refusals and Requests for Alternate Vaccine Schedules (AVS): National Surveys of Pediatricians. 2014 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Vancouver, British Columbia, May 5, 2014; Abstract #753688.
  34. Hitchcock WP, Almquist J, **Kimberlin DW**, O'Connor KG. HPV Vaccination and Tracking Completion of the 3-Dose Series: Results of a National Survey of Pediatricians. 2014 Pediatric Academic Societies / Society for Pediatric Research Annual Meeting, Vancouver, British Columbia, May 6, 2014; Abstract #754190.
  35. Almquist J, Hitchcock WP, **Kimberlin DW**, O'Connor KG. Influenza Immunization: Trends in Identifying High-Risk Patients, 2006 and 2013. 2014 Pediatric Academic

Societies / Society for Pediatric Research Annual Meeting, Vancouver, British Columbia, May 6, 2014; Abstract #754283.

36. Abzug AJ, Michaels M, Wald E, Jacobs R, Romero J, Sanchez P, Wilson G, Krogstad P, Storch G, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood S, Cloud G, Jester P, Acosta E, Whitley R, **Kimberlin D**, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates with Enterovirus Sepsis. IDWeek 2014 (annual meeting of the Pediatric Infectious Diseases Society, the Infectious Diseases Society of America, the HIV Medical Association, and the Society for Healthcare Epidemiology of America), Philadelphia, PA, October 9, 2014; Abstract #46967.
37. Oliver S, Potter J, Covington R, Tipler K, **Kimberlin D**, Prichard M. GenMark ESensor Respiratory Viral Panel in an Inpatient Pediatric Population. IDWeek 2014 (annual meeting of the Pediatric Infectious Diseases Society, the Infectious Diseases Society of America, the HIV Medical Association, and the Society for Healthcare Epidemiology of America), Philadelphia, PA, October 10, 2014; Abstract #46978.
38. Oliver S, Brennan S, Pati S, **Kimberlin D**, Boppana S, Ross S. Viral Diversity and Neutralizing Antibody Responses in Infants with Symptomatic Congenital CMV Disease receiving Antiviral Therapy. IDWeek 2014 (annual meeting of the Pediatric Infectious Diseases Society, the Infectious Diseases Society of America, the HIV Medical Association, and the Society for Healthcare Epidemiology of America), Philadelphia, PA, October 8-12, 2014; Abstract #46993.
39. James SH, Hartline CB, **Kimberlin DW**, Whitley RJ, Prichard MN. Genotypic Resistance Testing in Infants with Congenital Cytomegalovirus Disease Receiving Long-Term Oral Valganciclovir Therapy. IDWeek 2015 (annual meeting of the Pediatric Infectious Diseases Society, the Infectious Diseases Society of America, the HIV Medical Association, and the Society for Healthcare Epidemiology of America), San Diego, CA, October 8, 2015; Abstract #476.
40. Blumer J, Bradley J, Romero JR, Michaels MG, **Kimberlin DW**, Yamamoto G, Roberts G, Hossain M, Shortino D, Yates P, Adams B, Peppercorn A. Safety, Tolerability and Pharmacokinetics (PK) of Intravenous Zanamivir (IVZ) Treatment in Hospitalized Pediatric and Adolescent Patients with Influenza: A Phase II Open-Label, Multicenter, Single-Arm Study. IDWeek 2016 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), New Orleans, Louisiana, October 26-30, 2016; Abstract #57391.
41. Otto W, Myers A, LaRussa B, **Kimberlin D**, Jackson MA. Clinical and Laboratory Markers and Risk for CSF HSV DNA Persistence (pHSV) in Neonatal Disseminated and Central Nervous System (CNS) Infection. IDWeek 2016 (national meeting of the

- Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), New Orleans, Louisiana, October 26-30, 2016; Abstract #56827.
42. Rawlinson WD, van Zuylen WJ, Adler S, Dollard S, Fowler K, **Kimberlin D**, and Lazzarotto T, on behalf of the International congenital CMV Consensus Recommendations Group. Congenital Cytomegalovirus Infection in Pregnancy and the Neonate: Consensus Recommendations for Diagnosis, Prevention and Therapy. Congenital Cytomegalovirus Public Health and Policy Conference, Austin, Texas, September 26, 2016.
  43. Schmit EO, Headrick A, **Kimberlin DW**. Disseminated *Haemophilus influenzae* type a (Hia) infection in undiagnosed asplenia. Southern Society for Pediatric Research (SSPR), New Orleans, Louisiana, February 11, 2017.
  44. Shah SS, Hall M, Schondelmeyer AC, Berry JG, **Kimberlin DW**, Mahant S. Trends in Neonatal Herpes Simplex Virus Infection in the United States, 2000-2012. Pediatric Hospital Medicine 2017 (PHM 2017), Nashville, Tennessee, July 20-23, 2017. Abstract #A195.
  45. Marsico C, Aban I, Kuo H, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, James SH, Jester PM, Whitley RJ, **Kimberlin DW**, for the Collaborative Antiviral Study Group (CASG). Blood viral load (VL) not clinically meaningful in symptomatic congenital cytomegalovirus (cCMV) infection. IDWeek 2017 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Diego, California, October 6, 2017. Abstract #66384.
  46. James SH, Conner RL, **Kimberlin DW**, Whitley RJ, Prichard MN. Incidence of *UL97* Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving Six Months of Oral Valganciclovir Therapy. IDWeek 2017 (national meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America), San Diego, California, October 6, 2017. Abstract #66423.
  47. Reynolds C, Stein C, Atkinson P, Hurst A, **Kimberlin D**. XMEN Disease: An Unexpected Presentation of a Rare Primary Immunodeficiency. 2017 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology, Boston, Massachusetts, October 28, 2017. Poster #P267.
  48. Smithson M, Smalligan R, **Kimberlin D**, Eiland L, Abston P. When All Else Fails: A Case for Doxycycline in Pertussis. American Federation for Medical Research Southern Regional Meeting, New Orleans, Louisiana, February 22, 2018. Poster #321.



**PUBLICATIONS – ABSTRACTS – Submitted**

1. Akhtar LN, Bowen CD, Renner DW, Pandey U, Della Fera AN, **Kimberlin DW**, Prichard MN, Whitley RJ, Weitzman MD, Szpara ML. Genotypic and phenotypic diversity within the neonatal HSV-2 population. 2018 International Herpesvirus Workshop, Vancouver, Canada, July 21-25, 2018.